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SYNOPSIS 
Hashimoto’s Thyroiditis is an autoimmune disease of the thyroid gland characterised by 
thyrocyte death. Although it was previously thought that Hashimoto’s thyroiditis shared  
common aetiology with Graves’ disease, there is now significant evidence to suggest separate 
causal loci. The aims of this thesis were, i) to investigate HLA class II as a causal factor for 
Hashimoto’s thyroiditis ii) to investigate the potential role played by HLA class I MICA and 
MICB in Hashimoto’s thyroiditis. Several predisposing and protective loci within the HLA 
class II region were determined including the strongly associated DR4 haplotype and its 
component alleles. Of note DR4 is not associated with Graves’ disease providing evidence for 
a difference in the aetiology of autoimmune thyroid disease. There were no strong 
associations in MICA and MICB in the context of Hashimoto’s thyroiditis. Further work is 
required to screen the HLA gene region to determine additional casual loci for Hashimoto’s 
thyroiditis. As the HLA gene region is an area of strong linkage disequilibrium this additional 
screening is also required to determine the primary associated loci. The data presented in this 
thesis provides further evidence for a difference in the aetiology of Hashimoto’s thyroiditis 
compared to that of Graves’ disease.  
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CHAPTER 1: INTRODUCTION 
 
The immune system plays a key role in protecting the body against invading or foreign 
pathogens. The normal immune response is launched when immune cells recognise foreign 
pathogens in the host system. Upon recognition of the pathogen the immune cells attempt to 
neutralise the pathogens by various methods including recruitment of other immune cells, 
endocytosis/phagocytosis of small pathogens and initiation of necrosis of cellular pathogens. In 
autoimmune disease this response is directed not at a foreign pathogen but at the hosts own cells. 
The autoimmune response may differ in specificity, being directed at only one type of cell within 
one organ through to targeting several organs and systems within the body. The pathology of 
each disease will therefore be related to the cells, tissues and organs affected. Whilst originally 
autoimmune diseases were classified into two discrete groups (Goldsby and Goldsby 2003), 
‘organ’ specific and ‘non-organ’ specific later findings have shown that a spectrum is more 
appropriate. This is due to the fact that even in ‘organ’ specific diseases although one tissue may 
be the major target of autoimmunity others tissues are also targeted. 
1.1 Autoimmune disease 
 
 To understand how immune system regulatory mechanisms break down to cause autoimmunity 
the normal function of this system must first be examined. 
1.2 Immune system regulatory mechanisms 
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One of the key cells of the immune system are T lymphocytes. T lymphocytes begin as 
hemopoietic stem cells which are released from the bone marrow, at this stage showing no 
specific lineage. These early stem cells migrate to the thymus, changing into the T cell 
precursors, CD4-/CD8- T cells. To permit T cells to recognise a wide variety of antigens the T 
cell receptor (TCR) is encoded by a series of segmented genes which may be expressed in 
different combinations allowing for a large degree of diversity within the T cell population. At 
the point of entry into the thymus the CD4-/CD8- T cells have yet to rearrange the TCR gene 
segments. The CD4-/CD8- T cells remain in the thymus in this indeterminate state for around 
three weeks during which time they proliferate. After this stage the cells rearrange the TCR gene 
segments and begin to express TCRs on the cell surface. As the rearrangement of the TCR gene 
segments is a random process not all T cells will develop a combination which is functional and 
compatible with the host’s immune system requirements. Due to this factor a double selection 
process is implemented to ensure that the eventual T cell population contains cells which express 
useful versions of the TCR; a process which is involves screening out self reactive T cells before 
they are released into the periphery. 
 
Positive selection 
The first stage of the double selection process includes positive selection, whereby thymic 
cortical epithelial cells present peptides bound by HLA class I and II molecules. Naive 
CD4+/CD8+ thymocytes which show an affinity to either the HLA class I or class II molecules 
receive a protective signal. Those which do not interact, due to low affinity for the individuals 
own HLA molecules, do not receive the protective signal and die through apoptosis. This first 
Chapter 1 Introduction 
 
3 
 
stage eliminates thymocytes which are unreactive towards HLA bound peptides as this mimics 
the eventual process of antigen fragment presentation in a real immune response.  
 
Negative selection 
The initial stage of positive selection generates a mixture of pre-T cells which will react to a 
presented antigen. However due to the random TCR gene segment rearrangement, there will also 
be T cells which will react towards the host’s own cells within this initial group. The process of 
negative selection is designed to eliminate these potentially harmful T cells. Medullary thymic 
epithelial cells, dendritic cells and macrophages act as antigen presenting cells by displaying 
peptide bound HLA class I and HLA class II molecules for recognition by the T cell population. 
Pre-T cells which react too strongly to the presented HLA molecules receive the signal for 
apoptosis (Simmonds and Gough 2004a, Alberts 2002). AIRE has been shown to be expressed in 
medullary epithelial cells and is thought to play a role in the presentation of tissue restricted 
antigens from the periphery that T cells may encounter (Giraud et al. 2007, Kyewski and 
Derbinski 2004). This process effectively removes any T cells which would view the hosts own 
cells as harmful antigens and as a result mount an autoimmune response.  
 
This dual process of positive and negative selection should ensure that only T cells which are 
useful to the host’s immune reaction remain and are released from the thymus after this process. 
However one of the major flaws in this is that not all self antigens are present in the thymus, 
hence they cannot be presented in the negative selection process. This results in the possibility 
that some of the T cells which survive the selection process may still be self-reactive.  
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The mechanisms mentioned in the previous section should prevent any self reactive T cells from 
remaining in the host system. These pathways are, however, subject to dysfunction for a variety 
of reasons, a factor which may lead to the onset of AID.  
1.3 The immune system as a causal factor for disease 
 
As part of the normal healthy immune system a small number self reactive T cells are released 
into the periphery due to the absence of various self antigens in the thymus. If a breakdown in the 
negative selection process occurs then an unusually high number of self reactive T cells may be 
released into the periphery. A mutation in AIRE is thought to be a causal factor in this breakdown 
as it induces a reduction in the transcription of the organ specific self antigens found in the 
thymus (Liston et al. 2007). AIRE has been the subject of much debate over recent years 
concerning its role in autoimmune disease. Mutations in the AIRE gene are known to cause 
autoimmune polyendocrinopathy-candidiases-ectodermal dystrophy (APECED). Although 
APECED is itself a multi-organ disease patients often show other autoimmune conditions such as 
thyroiditis and T1D indicating that AIRE may play a role as a general autoimmune susceptibility 
locus. It has been demonstrated that individuals who are homozygous for AIRE mutations or 
double AIRE knockout mice show a greater level of immune disfunction than those who are 
heterozygous (Mathis and Benoist 2009). As a result it has been postulated that whilst individuals 
who are homozygous for AIRE mutations develop APECED those who are heterozygous for 
mutations show characteristics of other autoimmune disorders. In argument to this theory 
however a study investigating the expression of common mutations in AIRE in a cohort 
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comprising of individuals with T1D, Addison’s disease, GD or HT showed no association of the 
mutations (Meyer et al. 2001). 
 
Conversely, a breakdown in the positive selection process may also lead to inappropriate 
autoimmune responses. During the positive selection stages only T cells with high affinity to the 
presented peptides receive the protective signal necessary to avoid apoptosis. However if an 
abnormally large amount of any given peptide is presented then T cells with only weak affinity 
will also react (McIver and Morris 1998). These cells when released into the periphery will react 
to even small amounts of antigen. 
 
 As has already been stated some self reactive T cells will be released into the periphery with the 
assumption that in a working system these will be indentified and removed by CD4+ regulatory T 
lymphocytes (Tregs). Tregs present in the peripheral immune system, detect the presence of the 
self-reactive T lymphocytes and send a destructive signal causing apoptosis preventing them 
causing autoimmune attack (Abbas et al. 2004). A number of studies have shown that either a 
reduction in the number of Tregs or a reduction in the suppressive abilities of the Tregs may 
cause self reactive T cells to remain and lead to autoimmune disease (Brusko et al. 2008, Curotto 
de Lafaille and Lafaille 2002, Paust and Cantor 2005, Tang et al. 2004). 
 
Two of the most common autoimmune diseases are GD and HT, both of which are centred 
around autoimmune attack against the thyroid gland. In total AITD represents 2-5% of the iodine 
1.4 Autoimmune Thyroid Disease 
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replete western population. To be able to understand how autoimmunity in HT and GD affects 
the normal function of the thyroid gland, the regulatory system of the hypothalamic-pituitary axis 
in a euthyroid (defined as normal thyroid function) individual must be explored. 
 
Thyroid hormone production by the thyroid gland is controlled by a cyclical mechanism relying 
on both positive and negative feedback. The following describes the normal process of the release 
of thyroid hormones within a euthyroid individual.  
1.4.1 Mechanisms of thyroid function 
 
The Hypothalamus, located in the brain just below the thalamus, secretes thyrotropin releasing 
hormone (TRH) which acts as a stimulus to the anterior pituitary gland which is situated below 
the hypothalamus. This results in the release of thyroid stimulating hormone (TSH) from the 
anterior pituitary. The released TSH migrates to the thyroid gland where it binds to thyroid 
stimulating hormone receptors (TSHRs) (previously known as thyrotropin receptors). As the TSH 
binds to the TSHR it induces the catalyst thyroid peroxidase (TPO) to react with thyroglobulin 
(Tg) causing iodinisation (Deme et al. 1976, Chistiakov 2003), which results in the formation of 
thyroxine (T4). T4 is released from the thyroid and converted into its active form, triiodothyronine 
(T3), by deiodination in the target tissues. Although the majority of T3 is produced outside of the 
thyroid a small amount is produced within the thyroid by conversion of T4 whilst still in the 
gland. The serum levels of T4 and T3 control the release of TSH from the anterior pituitary via 
negative feedback; as serum levels of T4 and T3 increase, this is detected by the hypothalamus 
and anterior pituitary gland and less TSH is released (Deneareaz and Lemarchand-Beraud 1995). 
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This mechanism therefore allows a constant level of serum T4 and T3 to be maintained. The 
schematics of this process are shown in Figure 1.1. It is disruptions within this pathway that can 
lead to the symptoms exhibited in AITD.  
 
There are two main forms of disruption of the thyroid hormone system, hyperthyroidism and 
hypothyroidism which are key features of the common AITDs GD and HT, respectively. 
Although it is known that the thyroid and associated molecular pathways provide the basis for 
GD, the actual mechanisms by which the disease is caused still await clarification. The 
predominant feature of GD is hyperthyroidism. Atypical binding of TSHR autoantibodies 
(TSHRAb) to TSHR (McIver and Morris 1998) causes constant stimulation of the TSHR. This 
results in overactivity of the thyroid gland and hence the production of large quantities of thyroid 
hormones (Cooper 2003). Due to the presence of these antibodies the normal mechanism of 
negative feedback (see section 1.4.1) is disrupted. The TSHRAb bind to TSHR in place of TSH 
stimulating the thyroid to produce T4 and T3, an effect which replicates the mechanism of normal 
TSH binding. Whereas increasing serum levels of thyroid hormones would cause a reduction in 
the release of TSH due to negative feedback the TSHRAb continue to bind to TSHR 
independently of this negative feedback system. This causes a high concentration of T4 and T3 to 
be present in the serum. 
1.4.2 Graves’ Disease 
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Figure 1.1: The hypothalamic-pituitary axis 
 
 
 
 
TSH: Thyroid stimulating hormone 
TRH: Thyrotropin releasing hormone 
T4: Thyroxine 
T3: Triiodothyronine  
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The first few descriptions of the clinical manifestations of GD by Parry (Andrew 2004) and 
Graves (Weetman 2000) led the way for further investigation and the full range of symptoms 
associated with GD were soon uncovered. Early findings of hyperthyroidism, diffuse goitre and 
exophthalmos were validated and what had previously been described as ‘palpitations’ were 
attributed to tachycardia and arrhythmia; now recognized as a common symptom. In addition 
increased bowel frequency, heat intolerance and hyperhidrosis of the hands (excessive sweating), 
tremor and aspects of  the ophthalmopathy described in earlier findings (also known as thyroid 
eye disease (TED)) were also attributed to the effects of GD (Simmonds and Gough 2004b). The 
onset of GD is typically in the 4th decade of life and a 5-10 fold increased female preponderance 
is seen (Tunbridge et al. 1977).  From the beginning GD was described as a disorder of the 
thyroid, however it was not until the 1956 study by Adams and Purves (Adams and H.D. 1956) 
that the underlying mechanism was explored. This study concerning the assay of thyrotropins led 
to the discovery that autoantibodies directed at the thyroid stimulating hormone receptor (TSHR) 
may be the cause of the hyperthyroidism experienced in GD (Adams and H.D. 1956, Evans 
2002). The involvement of TSHRAb is now accepted and it has been found that  90% of GD 
patients test positive for TSHR autoantibodies (Evans 2002). In addition the remaining 10% may 
also exhibit TSHRAb but in such small amounts that current assays cannot detect them.  
 
The mechanism outlined in the section 1.4.1 describes the cyclical process of the normal control 
of thyroid hormone production, in HT this cycle is disrupted and hypothyroidism ensues. The 
death of thyrocytes begins to increase beyond the rate at which they are replaced in a healthy 
1.4.3 Hashimoto’s thyroiditis 
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euthyroid individual the thyroids ability to produce T3 and T4 is reduced. This is due simply to a 
reduction in the number of cells able to produce the hormones. In turn this leads to a decrease in 
the serum levels of T3 and T4 and hence the levels of these hormones that are detected by the 
hypothalamus. In reaction the hypothalamus increases the output of TRH stimulating the anterior 
pituitary to increase the production of TSH in an attempt to stimulate the thyroid to produce 
greater quantities of T3 and T4 (see Figure 1.2). Contrary to the eventual outcome of 
hypothyroidism this can in fact lead to a transient state of hyperthyroidism caused by the 
excessive production of T3 and T4 as a result of this feedback loop. This transient thyrotoxicosis 
in combination with an initial and incorrect diagnosis of GD may also be the reason for some 
theories which postulate that GD can transform in to HT.     
 
In 1912 Hakaru Hashimoto first described four patients who had attended his clinic over the 
course of 6 years (Hashimoto 1912). All four patients he noted were over 40 years of age and 
female. These patients presented with slightly varying symptoms, the one common symptom to 
all however was the appearance of a large ‘tumour’ in the neck. Hashimoto performed surgery on 
all four patients and found that the thyroid gland was enlarged in each. He also ruled out the 
possibility of this being a normal ‘tumour’ as no metastases were reported and all other organs 
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Figure 1.2: Mechanism of action of thyroid destruction 
 
 
 
 
 
TRH: Thyrotropin releasing hormone 
T4: Thyroxine 
T3: Triiodothyronine  
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seemed healthy at the time (Hashimoto 1912). Following the operations Hashimoto kept tissue 
samples to further investigate the cause of this enlargement. His most prominent finding was that 
lymph tissue was abundant in the thyroid of these individuals, a fact which resulted in the 
alternate and original name for HT, Struma lymphomatosa (Hashimoto 1912). 
 
These early findings provided the first insight into the disease. It was not by coincidence that the 
4 patients Hashimoto investigated were all female as a high female preponderance is displayed in 
HT with women being five to seven times more likely to be affected than men (Vanderpump et 
al. 1995). Again the ages of the four initial patients coincide with the later finding that HT most 
commonly occurs in the fourth or fifth decade of life (Vanderpump et al. 1995).  
 
Diagnosis  
Initially the symptoms of HT may not be apparent. As the disease progresses and hypothyroidism 
becomes more severe, visible symptoms may occur. Common symptoms include intolerance to 
cold, mild weight gain, fatigue, constipation, dry skin, hair loss, heavy and irregular menses, 
difficulty concentrating or thinking, joint stiffness and facial swelling (Hashimoto 1912). In some 
cases mild thyrotoxicosis (a sometimes transient elevation of free T3 and T4. hyperthyroidism is a 
subset of this) and in extreme cases myxedema (dermal and cutaneous edema caused by deposit 
of large amounts of mucoproteins in the tissues) leading to a coma may occur. An enlarged 
swelling in the neck or goitre may also be present as a result of either inflammation or 
hashitoxicosis and late in the disease a small or atrophic thyroid gland. If a goitre is present it 
may be unilateral or bilateral and will be diffuse and firm with pyramidal lobe enlargement.   
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If HT is suspected then levels of T3 and T4 should be investigated to confirm biochemical 
hypothyroidism. Furthermore antibody tests are carried out to confirm the diagnosis with positive 
antibodies to Tg or TPO indicating HT. 
 
Treatment 
The effects of the disease cause decreased levels of T4 to be present hence levothyroxine sodium, 
a synthetic form of T4, is used as a replacement treatment. By replacing the T4 only, the lost T3 
can also be regained via outer ring deiodination of T4 as would occur in a euthyroid patient (see 
Figure 1.1). Whilst it is generally accepted that levothyroxine therapy is a suitable course of 
treatment the actions of the levothyroxine and the dosage required are often brought in to 
question. The dose required must be carefully adjusted throughout the course of the disease. 
Some cases of HT result in a euthyroid state and therefore the withdrawal of therapy entirely may 
be necessary in some instances (Lorini et al. 2003). 
 
Other treatments have been postulated and studied, one of the most notable being the use of 
selenium. The deiodination of T4 to produce T3 (see Figure 1.1) occurs via enzymes containing 
selenocysteine. Whilst three types of deiodination enzyme are present in the body, each acting in 
different tissues all three are reliant on adequate resources of selenocysteine, a source of 
selenium. In addition to this glutathione peroxidases are selenium based antioxidant enzymes 
which catalyse the breakdown of reactive oxygen species such as hydrogen peroxide. A reduction 
in the normal levels of these selenoproteins can lead to inefficient and incomplete breakdown of 
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the reactive oxygen species and result in inflammation. This may be a causal factor in not only 
HT but several AIDs (Duntas 2008). In support of these theories and findings selenium 
deficiency has been shown to have an adverse effect on the deiodination rate in rats (Stefanou 
and Wooster 1975) whilst selenium therapy has been shown to have a suppressive effect on TPO 
antibodies in human studies (Mazokopakis and Chatzipavlidou 2007).  This preliminary evidence 
suggests that selenium may be beneficial in the treatment of HT. There is however no evidence to 
indicate that selenium improves thyroid function significantly and is therefore not used routinely 
as a treatment for HT.  
 
Levothyroxine treatment manages HT resulting in lifelong medication, rather than cure it. There 
has been little investigation in to the possibility of more aggressive treatments involving targeting 
the autoantibodies themselves or a more permanent cure.  
 
There is little available data on the pathogenesis of HT. Whilst some aspects of the etiology are 
known (see section 1.5) the actual mechanisms and pathways that result in the formation of 
disease are harder to elucidate. The involvement of the death of thyrocytes and the resulting 
impact on T4 and T3 plasma levels is accepted. However, although thyrocyte death is a known 
fact of HT the mechanism behind it remains unclear. There are several theories and studies which 
support various possible mechanisms of either apoptosis or necrosis of the thyrocytes (see figure 
1.3).   
1.4.4 Pathogenesis of Hashimoto’s Thyroiditis 
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Figure 1.3: Possible pathogenic pathways of Hashimoto’s thyroiditis  
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Tumour-necrosis factor mediated apoptosis  
As thyrocyte death is a feature of HT changes within the pathways causing apoptosis may be 
linked to HT onset. One of the theories suggested centres around tumour-necrosis factor 
receptors, in particular the death receptor Fas (also known as TNF receptor superfamily, member 
6) and the Fas ligand (FasL) and their roles in apoptosis. One method by which apoptosis occurs 
is that death receptors such as Fas on the  target cell interacts with the ligands present on the T 
cell such as FasL causing the apoptotic chain to commence. The first step within apoptosis 
involves the activation of pro-caspases 8 or 10. Active caspases 8 or 10 initiate the mitochondrial 
membrane of the target cell to become damaged, cellular respiration to cease and finally the 
activation caspases 3, 6 and 7 which lead to fatal changes in the cell membrane, cytoskeleton and 
nucleus causing cell death (Lumachi and Basso 2002).  The study of Fas and FasL highlights the 
opposing natures of HT and GD. Several studies have shown that Fas/FasL were upregulated and 
expressed in thyrocytes of HT patients indicating that this raised level may be responsible for the 
thyrocyte destruction seen as the disease progresses (Salmaso et al. 2002, Xu et al. 2007, Stassi 
and De Maria 2002, Chistiakov 2005).  
 
The Fas mediated thyrocyte death seen in HT is not just due to the presence of T cells, these 
thyrocytes are able to produce both Fas and FasL on their cellular surface (Giordano et al. 2001). 
This allows fratricidal apoptosis to occur where one thyrocyte induces the death of another 
independent of T cell interaction (Lumachi and Basso 2002, Chistiakov 2005). Interestingly, 
Interleukin-1β (IL-1β) is expressed in the thyroid, which stimulates Fas expression in normal 
thyrocytes pointing towards a potential pathway for the upregulation seen of Fas/FasL. It remains 
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unclear however whether the upregulation of Fas/FasL seen in HT patients is independent of IL-
1β or not.  
 
Autoantibodies 
Although it is clear that autoantibodies are present in HT including TPO and Tg, their exact role 
in the onset and pathogenesis of the disease remains to be validated. At present it is unclear 
whether the autoantibodies present are the trigger or the result of an autoimmune attack. This is 
due in part to the variable titres of autoantibodies detected in HT patients and the presence of 
autoantibodies (albeit in lower levels) in healthy euthyroid patients (Nielsen et al. 2008).  
 
The TPO autoantibodies found in HT are able to fix complement. As such, a theory has been 
proposed suggesting that TPO autoantibodies may be responsible for the thyrocyte death seen in 
HT (Blanchin et al. 2003, Stassi and De Maria 2002). The complement pathway plays an integral 
role in the innate immune system and may also be utilised by the adaptive immune system. There 
are three complement pathways, classical, alternative and lectin which, whilst different in the 
initial stages, all result in similar final stages of the pathway. The classical complement pathway 
is the only one which is typically due to a specific immune response and is mediated by 
antibodies (the alternative pathway is stimulated by direct contact with pathogen surface 
molecules whereas the lectin pathway is stimulated by mannose binding lectin). At the end of the 
complement pathway the membrane attack pathway is activated and subsequently the membrane 
attack complex is formed from cytokine fragments C5b, C6, C7 and C8. This complex is a 
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transmembrane channel which effectively changes the osmotic pressures on the cell causing 
necrosis.  
 
Environmental cause 
One theory suggests that HT is either caused, or the onset of disease induced in an already 
predisposed individual, by an inflammatory event. An environmental causal factor such as 
variation in iodine levels or bacterial/viral infection may affect the thyroid causing an 
inflammatory response and an influx of dendritic cells and macrophages which could be the 
trigger to activate other immune cells resulting in an autoimmune response. (see section 1.5.1) 
(Chistiakov 2005). This theory also links to the Selenium therapy mentioned in the discussion of 
the treatment of HT in section 1.4.3. A deficiency in the levels of selenium would cause a 
prolonged and intensified inflammatory response (Duntas 2008). This may then cause a 
heightened sensitivity to pathogens resulting in self antigens being recognised as non-self.  
 
The vast majority of the original work concerning AITD was performed using either solely GD 
patient cohorts or mixed cohorts where GD and HT were grouped together. As a result the work 
discussed in the following sections is concentrated on GD and mixed AITD cohorts.  
1.5 Genetic and environmental causal factors of AITD 
 
Some of the most striking evidence for a genetic basis to AITD can be seen in the twin studies 
performed. In two studies of Danish twins GD concordance rates of 0.35-0.36 and 0-0.07 were 
found for monozygotic (MZ) and dizygotic (DZ) twins respectively (Brix et al. 2001, Brix et al. 
Chapter 1 Introduction 
 
19 
 
1998). In a similar Californian based study concordance rates of 0.17 and 0.019 were found for 
MZ and DZ twins respectively (Ringold et al. 2002). A further study by Brix et al. attempted to 
investigate HT in a Danish twin cohort. Only 24 HT patients were used with 3 MZ pairs 
displaying concordance and 0 DZ pairs showing concordance. The low numbers were taken into 
consideration and “crude” concordance rates of 0.55 for MZ twins and 0 for DZ twins were 
reported (Brix et al. 2000). Although this does point towards a genetic component to HT the 
study requires replication in a much larger cohort to verify the findings. This method of using the 
comparison of MZ and DZ twin pairs is well established for demonstrating the existence of a 
genetic component in the causal factors of a disease (Osborne et al. 1958). Whilst MZ twins 
share one hundred percent of their genetic material DZ twins do not, as each is formed from a 
separate fertilised egg. In most cases however, both MZ and DZ twins share environments hence 
the comparison of concordance rates between MZ and DZ twins can help elucidate whether the 
causal factors for a disease are genetic and/or environmental factors. The two sets of concordance 
rates gained from the Danish and Californian GD studies along with a concordance rate of 0.036 
between probands and first degree relatives (defined as a relative who is separated by a single 
meiotic division from the proband and hence shares around 50% of genetic information, i.e. 
parent, sibling, child) in the Californian (Ringold et al. 2002) indicate that there is a definite 
genetic influence; however they also demonstrate that there are other aspects which need to be 
investigated concerning the causal factors affecting the development of AITD. With a disease 
whose only causal factors are genetic, a concordance rate approaching 1.00 would be expected 
for the MZ twin sets. The concordance rates for MZ twins in the GD studies fall far below the 
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1.00 mark indicating that the development of GD in an individual is influenced by factors other 
than a germline variant, be it a somatic variation or environmental factor.  
 
These and other familial clustering and twin studies have clearly demonstrated that AITD does 
not occur because of a single gene defect and does not follow a simple pattern of Mendelian 
inheritance (Evans et al. 1967, Stenszky et al. 1985, Farid 1981).  With a single gene defect a 
clear path of inheritance from parent to child would be expected, although AITD clusters in 
families it does not necessarily passed from one generation to another and often is found to skip 
generations (Farid 1992). This irregular pattern of inheritance is characteristic of many of the 
common medical conditions which are now referred to as complex diseases in which both genetic 
and environmental factors contribute to disease development (Simmonds and Gough 2004a). This 
pattern may also imply that AITD is caused by genetic variations conforming to the ‘two-hit 
mutation’ theory (Nordling 1953, Knudson 1971). This theory suggests that a germline 
polymorphism or mutation is indeed inherited but that this alone is not enough to cause disease. 
For the disease to develop a second somatic or germline polymorphism or mutation must also be 
present. Although referred to as the two hit mutation hypothesis a disease may require three or 
more mutations to fully develop (Tomlinson et al. 2001). This theory may well account for the 
erratic pattern of inheritance seen in AITD. If a single mutation is inherited then the progeny will 
have the potential to develop AITD but will require at least one other mutation to occur for the 
eventual disease state to develop. This has led to the use of statistical modelling as a possible 
means of identifying the genetic contribution to AITD. The previously mentioned study by Brix 
et al. which investigated the concordance rates in Danish twins used statistical modelling to 
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determine the impact of genetic contribution to GD which they proposed was around 79% (Brix 
et al. 2001). This indicates that the inherited component to AITD is likely to arise from numerous 
common and also rare genetic variants, with contributions from all over the human genome, 
producing a “DNA fingerprint” that confers an increased risk for the development of disease 
(Brickman and Shoenfeld 2001).  Although the genetic factors are almost certainly the main 
causal factors in AITD the impact of potential environmental factors should not be ruled out.  
 
To investigate the majority of environmental factors patients are interviewed and the relevant 
history taken including family history if applicable. This method of data collection may cause 
inconsistencies in the data for these studies due to the reliance on patient testimony for a number 
of environmental factors. Embarrassment for example may lead a patient to under-quote the 
number of cigarettes smoked a day or units of alcohol consumed. For the vast majority of 
environmental factors however previous notes and documentation may be available to aid with 
this possible pitfall. A range of statistical tests may be performed on the collated data including 
assessment of the mean for factors such as age of onset, comparison of environmental factors 
against physical or biochemical findings such as smoking versus NOSPECS score or variations in 
physical and biochemical findings between males and females. 
1.5.1 Environmental Factors in AITD 
 
Infection 
It remains unclear as to whether infection is a significant causal factor for HT (see section 1.4.3 
for further information on the pathogenesis of HT). There has been some evidence however for 
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bacterial infections, in particular Yersinia enterocolitica as causal factors for both HT and GD 
(Corapcioglu et al. 2002).  Y.enterocolitica displays molecular mimicry to TSH whereby the 
bacteria closely mimics the binding sites displayed on TSH without being identical. As the 
binding sites are not completely identical the host system recognises the presence of a foreign 
antigen and launches an immune attack accordingly. The similarity of the Y.enterocolitica 
binding sites to the TSH binding sites is so great however that cross reactive antibodies, those 
which respond to TSH rather than Y.enterocolitica can occur. Whilst some weak correlation 
between autoantibody titres and Y.enterocolitica infection have been shown (Corapcioglu et al. 
2002) there is little evidence to support this particular model of infection as a causal factor for 
AITD.  
 
Smoking 
Conventionally smoking has been associated with increased risk of AITD and associated 
symptoms, in particular the severity of thyroid eye disease in GD (Manji et al. 2006, Fukata et al. 
1996, Holm et al. 2005, Vestergaard 2002). The effects are presumed to centre on two 
constituents of cigarette smoke, nicotine and tar. They have been shown to affect the expression 
HLA, most notably that of HLA-DR (Muller et al. 1995). This change in expression causes 
changes in the presentation of antigens by APCs hence the actions of T cells during positive and 
negative selection (Vestergaard et al. 2002) (see section 1.2).  There is some evidence to suggest 
that smoking can have a positive effect on at least one aspect of HT though. Several studies have 
shown negative correlations between smoking and TPO antibodies in patients with AITD 
(Strieder et al. 2003, Goh et al. 2004, Belin et al. 2004). It is thought that one explanation is the 
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inhibitory effect of thiocynate, a component in cigarette smoke, on iodide organification in the 
thyroid (Fukayama et al. 1992). As organification is catalysed by TPO a reduction in the TPO 
levels may give rise to a smaller immune response against that particular antigen.  
 
Iodine 
Iodine is a central part of the normal mechanisms of the thyroid with both T3 and T4 being iodine 
based hormones (see section 1.4.1). Several animal based studies have shown the ability of 
increased iodine intake to affect normal thyroid function and induce hypothyroidism and 
thyroiditis (Rasooly et al. 1996, Follis 1964, Allen et al. 1986). Furthermore there is evidence 
that Tg reactive T cells show a greater affinity for highly iodinated Tg than low iodinated Tg 
(Sundick et al. 1987). An increased dietary intake of iodine may therefore lead to a heightened 
immune response increasing the possibility of an inappropriate response such as one directed at 
self.  
 
It is thought that the involvement of the TPO autoantibodies play a more prominent role than 
those of the Tg autoantibodies in HT (see section 1.4.3). Increased dietary iodine has been shown 
to cause hypothyroidism, in particular when iodine supplements  are introduced in geographical 
areas of poor iodine intake (Harach et al. 1985). However this observed hypothyroidism may not 
be associated with the autoimmune forms seen in AITD. 
 
 
  
Chapter 1 Introduction 
 
24 
 
1.6 Genetics of AITD 
It has long been established that there is a genetic component to both HT and GD. The primary 
concern of early AITD studies was to determine whether there was a genetic component to both 
GD and HT rather than assessing the exact causal loci. As has been previously mentioned, little 
work has been done concerning HT alone and the majority of the early genetic studies have been 
performed using either mixed cohorts or solely GD cohorts. A variety of different methods have 
been used to investigate the genetics of AITD including case control and genome wide studies.   
 
1.6.1 Identification of Genetic causal factors 
Candidate Gene studies 
Candidate gene studies are based on a prior knowledge or theory of the pathogenesis of the 
disease or of similar diseases. This may be either from a general hypothesis, such as the 
investigation of the genes involved in the immune response in autoimmune diseases or from a 
previous non-genetic study where a protein or molecule was found to be present in abnormal 
amounts in the sera of affected patients. In AIDs there is a certain amount of crossover of genetic 
causal factors. The common autoimmune association means that a gene associated with one AID 
may well be associated with another, in particular if the gene or gene region in question plays a 
major role in the autoimmune response in a healthy individual.   
 
Once a gene has been chosen variations within that region are investigated in candidate control 
studies by comparison of unrelated affected subjects with control subjects who are unrelated and 
unaffected and are matched to cases for sex, age, ethnicity and all other variables with the 
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exception of disease state . Alternatively in family based studies the affected subjects may be 
compared with unaffected individuals from the same family.  
 
Linkage disequilibrium-mapping and Tag Single nucleotide polymorphisms (SNPs) 
Early candidate gene studies examined only one or two polymorphisms due to the constraints of 
time, expense and knowledge of the gene region. This lead to some genes being falsely excluded 
as susceptibility loci as the small portion tested was not associated but other areas within the 
same gene region were later discovered to be associated such as the early work performed on 
TSHR (Cuddihy et al. 1995). Linkage disequilibrium (LD) is a measure of the probability that 
two markers will be inherited on the same haplotype (see chapter 2 section 2.8.4 for further 
detail). Utilising the strong LD seen in some regions one SNP can be chosen which will give a 
good representation of the associated LD block and several other SNPs within that block 
allowing a more comprehensive coverage of the gene region of interest (see Figure 1.4). This 
allows for an estimation of a large number of genotypes by only typing a few that capture, or tag, 
a block of LD (Johnson et al. 2001).   
 
Genome wide linkage studies  
Genome-wide screens can be used to investigate entire genomes for loci which show signs of 
association with disease. One strength of genome wide screens is that a prior hypothesis is not 
required. One method used is based on the presence of short tandem repeats (STRs) within the 
genome. These STRs are normally composed of di-, tri- or tetra-nucleotide repeats and are known 
as microsatellites. Microsatellites are highly polymorphic; in combination with their  
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Figure 1.4: Haplotype formation of SNPs in high and low LD 
 
 
 
 
 
 
 
Complete LD allows for only one haplotype to be formed. Low levels of linkage allow for several 
different SNP combinations.  
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frequent appearance in the genome they can be used as markers to identify associated loci.  
 
Following the completion of the first family based genome wide linkage study in type 1 diabetes 
(T1D) (Davies et al. 1994), many investigators adopted this approach to identify novel 
susceptibility loci for complex diseases. Using microsatellite markers, a number of linkage 
studies and genome wide scans have been conducted in AITD (Tomer et al. 1999, Tomer et al. 
2003, Taylor et al. 2006, Sakai et al. 2001). One of the first of these was performed by Tomer et 
al in 1999 on 56 multiplex families and identified six regions of linkage to GD, HT and AITD, 
AITD-1 (6p), GD-1 (14q31), GD-2 (20q11.2), GD-3 (Xq21), HT-1 (13q32) and HT-2 (12q22) 
(Tomer et al. 1999).  HT-1 was found to show linkage in all HT families within the cohort 
whereas HT-2 was linked only in the European HT families and not in the North American 
families. Upon expansion of the dataset GD-3 and HT-1 were not replicated and three new 
markers D7S502 (7q), D8S284 (8q) and D10S537 (10q) were proposed as susceptibility loci 
(Tomer et al. 2003). Disparity is also seen when comparing these studies to that of Taylor et al, 
where only 3 areas of possible susceptibility were identified 18p11, 2q36 and 11p15 (Taylor et al. 
2006).   
 
Whilst putative loci have been reported for AITD, few if any linkages have been convincingly 
replicated and none of the chromosomal regions of linkage, including HT-2, have led to the 
identification of a novel locus. The conclusions drawn from many of these studies is that linkage 
analysis alone is unlikely to deliver a significant number of new loci in complex disease, largely 
in part, because of inadequate sample size (Wang et al. 2005).   
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A recent initiative has aimed to overcome many of the problems seen in previous genome-wide 
screens and linkage studies. The Wellcome Trust Case Control Consortium (WTCCC) has 
conducted several large association studies in which the cohort size is far greater than previous 
studies. The second major improvement made in these studies is the switch from microsatellite 
markers to the use of SNPs. Whilst new STRs appear more frequently than new SNPs the overall 
number of SNPs is normally greater than the overall number of STRs in a given region (Xing et 
al. 2005, Ulgen and Li 2005). For this reason the use of SNPs in this project has allowed a more 
detailed analysis of the genome by investigating a greater number of markers.  
 
The WTCCC investigated 14,436 non-synonymous SNPs throughout the genome and 897 SNPs 
from within the HLA region, in 4 diseases; GD, breast cancer, multiple sclerosis and ankylosing 
spondylitis. For each disease a cohort of 1000 samples was used and a common control cohort of 
1500 samples. Several associated SNPs were discovered for GD including numerous associations 
within the HLA region, 3 SNPs in FCRL5 and one in each of FLJ32784, FCRL3, MRPL53, 
HDLBP, PPP1R3B, ADRA1A, ZNF268, TEKT1, ADCYAP1, AMH and UTX. An associated SNP 
was also found in TSHR in an expanded data set (Burton et al. 2007).  
 
Problems surrounding the identification of the genetic causal factors for HT  
The primary difficulty in elucidating the genetic components of AITD is that the individual 
genetic effects at each locus are small. As previously stated AITD is not a monogenic disease, the 
collective effect of the multiple mutations and polymorphisms may be considerable and indeed 
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enough to confer disease. However it seems likely that the majority of individual loci confer odds 
ratios (OR) for the development of disease between 1.2 and 1.5 (Wang et al. 2005).  
 
 As a consequence, the sample sizes in almost all the early candidate gene population based case 
control studies, have been too small to detect these effects, whilst at the same time generating 
non-reproducible false positive results (Ioannidis et al. 2001). Sample sizes and power 
calculations depend greatly on allele frequencies and the size of effect expected. Generally, 
therefore, whilst some small studies have identified and excluded true specific effects, those with 
less than 500 cases and 500 controls could be viewed with caution as they may be too small to 
provide reliable, reproducible data (Dahlman et al. 2002).  
 
1.7 Genetic Causal Factors for AITD 
There are few indentified genetic causal factors for HT. Of note are the HLA region (discussed in 
chapter 3) and CTLA4, Tg and PTPN22. It is worth however investigating the studies showing 
associated regions to GD and general AITD cohorts as they may provide some insight into future 
candidate genes for HT. (see diagram 1.5 for the schematic of the interactions of the molecules 
encoded by these genes)  
 
  
Figure 1.5: Some of the suggested and confirmed susceptibility loci for GD involved in antigen presentation to T cells 
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CTLA4 
CTLA4 is a negative regulatory molecule central to the immune system. It inhibits T cell 
responses by opposing the action of CD28, molecule which promotes T cell actions (Gough et al. 
2005). CTLA4 was first reported to be associated with GD (Yanagawa et al. 1995), since then it 
has also been shown to be associated with HT (Ueda et al. 2003) and many AIDs (Gough et al. 
2005). Initially only four polymorphisms were known and investigated including an (AT)n repeat 
sequence in the 3’ untranslated region which was associated with potential functional effects 
(Braun et al. 1998, Vaidya et al. 1999, Yanagawa et al. 1995, Heward et al. 1999a).  
 
At this stage the primary disease determinants within this gene region remained unknown. A 
large resequencing effort and fine mapping of all common variants detected within the gene 
allowed GD susceptibility to be mapped to four SNPs (CT60, J030, JO31 and JO27_1) within a 
non-coding 6.1kb region. The common allelic variation (G allele) of the CT60 SNP was 
associated with lower messenger RNA levels of the soluble alternative splice form of CTLA. The 
CT60 SNP was shown to have an association with HT (OR=1.45, 95%CI=1.17–1.80); P=0.0005) 
in the same study (Ueda et al. 2003). Association of the CT60 SNP with GD has since been 
confirmed by several independent studies including a recent meta-analysis using data collected 
from 7246 GD patients which showed a significant association (Kavvoura et al. 2007). The 
association has also been confirmed in HT (Donner et al. 1997). In contrast to the large numbers 
available for the GD studies and meta-analysis it should be noted that the two HT studies had 
patient cohorts of only 228 and 73 respectively and that similar studies showing association of 
CTLA4 with HT have also used small patient cohorts (Kotsa et al. 1997, Nithiyananthan et al. 
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2002). These findings have yet to be replicated in large numbers. The mechanism by which 
polymorphism of CTLA4 acts to inhibit autoimmunity and specifically the role of soluble, as 
opposed to full length CTLA4, currently remains unknown (Gough et al. 2005), but is the subject 
of ongoing functional analysis.  
 
Tg 
Two genome wide linkage studies have reported evidence for linkage between AITD and 
chromosome 8q24 (Sakai et al. 2001, Tomer and Greenberg 2004). This is however inconsistent 
with the findings of the largest linkage study to date which observed no evidence for linkage 
between chromosome 8q24 and AITD nor GD or HT (Taylor et al. 2006).  Tg maps to 
chromosome 8q24 and a number of candidate gene case control association studies have been 
conducted examining both microsatellite (Collins et al. 2003) and SNP markers (Ban et al. 2003, 
Collins et al. 2004a)  The original study by Collins et al. demonstrated weak association of the 
intron 27 Tg microsatellite with AITD (P < 0.001) (Collins et al. 2003). It was however 
presumed at the time that this may be a false result. This conclusion was strengthened by the 
second study performed by Collins et al. in which no association of Tg with AITD was noted 
(Collins et al. 2004a).  Whilst no association was found in these studies Ban et al. described 
association of a SNP cluster in exons 10 and 12 and also of a separate SNP within exon 33 (Ban 
et al. 2003). Although Tg autoantibodies are seen in both HT and GD, making Tg a viable 
candidate gene, findings have been inconsistent with the largest association study to date 
providing no evidence for association between Tg markers and AITD (Collins et al. 2004a).  
However, as was the case with the early CTLA4 association studies only a fraction of the gene 
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has been tested for association with AITD. This may be improved upon in further years following 
the resequencing of all exons within Tg and the genotyping of all exonic SNPs (Ban et al. 2003).   
 
PTPN22 
PTPN22 located on chromosome 1p13 encodes a protein PTPN22 (also known as LYP). PTPN22 
inhibits T cell signalling by dephosphorylating autophosphorylation sites on Src kinases hence 
preventing activation of T cells. PTPN22 interacts with several accessory molecules including 
protein tyrosine kinase Csk and Grb2 (Brand et al. 2005, Bottini et al. 2004). Initially association 
of PTPN22 was reported in T1D (Brand et al. 2005, Smyth et al. 2004) and this was soon 
followed by positive associations in AITD (Smyth et al. 2004, Velaga et al. 2004) and also in 
other autoimmune diseases including systemic lupus erythematosus (Kyogoku et al. 2004) and 
rheumatoid arthritis (RA) (Begovich et al. 2004).  
 
The association of PTPN22 with several AIDs suggests that this may be a general susceptibility 
locus for AID. This theory is supported by the functional knowledge of both the general role of 
PTPN22 as mentioned above and also the specific effects of the C and T allelic variants of the 
associated 1858 SNP (rs2476601). It has been demonstrated that the change from the major allele 
C to the minor allele T causes a change of the amino acid sequence encoded by this region at 
position 620 in PTPN22 (Bottini et al. 2004). The common allele encodes arginine and the rarer 
allele tryptophan. This change in amino acid also changes the binding properties of PTPN22 with 
protein tyrosine kinase Csk with the rarer allele form tryptophan leading to a reduction in the 
ability of PTPN22 to inhibit T cell activation. This results in a change from arginine in the 
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common form to tryptophan in the rarer allele, which in turn affects the binding properties of 
PTPN22 with protein tyrosine kinase Csk. The rarer T allele leads to a reduction in the ability of 
PTPN22 to inhibit T cell activation, resulting in an exaggerated immune response (Bottini et al. 
2004). 
 
The rs2476601 SNP appears to be common to a number of AIDs, however other  independent 
associations within the PTPN22 gene region have been detected, with different patterns of 
association observed in individual diseases (Michou et al. 2007, Heward et al. 2007, Carlton et 
al. 2005, Onengut-Gumuscu et al. 2006). In GD several disease specific haplotypes have been 
identified, in particular the strongly associated AATTCT 6.77x10-8 and the strongly protective 
AACTTT 3.7x10-5 (both corresponding to alleles from each of the following SNPs (rs2488458 , 
rs12730735,  rs2476601, rs1310182, rs1217413 and rs3811021) (Heward et al. 2007). These 
disease specific haplotypes suggest that the mechanism by which PTPN22 confers susceptibility 
to GD may be different, for example, to T1D and RA. 
 
In addition there is one notable report of HT specific association in a cohort of size. In a study by 
Criswell et al. 256 multiplex families which contained at least two different autoimmune diseases 
within the family were investigated for association with PTPN22.  From the families chosen 746 
affected individuals, of which 194 were affected with HT, were compared to 2,064 unaffected 
control subjects. An association of the T allele of rs2476601 SNP with HT was noted with 
OR=1.77, 95%CI=1.31-2.40 (Criswell et al. 2005).  
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Commonality and distinction in AITD genetic causal factors 
Whilst for many genetic studies HT and GD are combined and referred to as AITD, which 
suggests a single diseases state, more information is becoming available to suggest that these two 
diseases are distinct conditions. HT and GD represent two extremes of the AITD spectrum. HT is 
primarily a hypothyroid disorder characterized by the presence of hypothyroidism together with 
positive antibodies directed against Tg or TPO. In contrast GD is typified by hyperthyroidism and 
autoantibodies directed against the TSHR in addition to those against Tg and TPO. Many of the 
genetic studies focusing on AITD have either grouped both HT and GD patients together as a 
single cohort or have focused solely on GD. This is in part due to the lack of large cohorts 
available for HT studies; hence to obtain the power necessary for a viable statistical result the 
cohorts have been predominantly GD where larger cohorts are more readily available. This, in 
turn, means that whilst many of the causal genetic factors for GD have been established there are 
few confirmed results for HT. Interestingly although GD and HT share several genetic factors, 
there are genetic differences already established between these diseases for the CD40 and TSHR 
genes. 
 
CD40  
Genome wide microsatellite screening has linked chromosome 20q11.2 to GD and has been 
designated GD-2 (Tomer et al. 1999, Tomer et al. 2003). Further weak support for this result was 
present in 12 UK Caucasian sib-pairs who appeared to have dominantly inherited GD (Pearce et 
al. 1999), although no evidence for linkage was found in the largest linkage study to date of 1119 
Caucasian sib-pairs (Taylor et al. 2006).  CD40 has been mapped close to the initial region of 
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linkage and a single Kozak SNP has been reported to be associated with GD in a study by Tomer 
et al. (Tomer et al. 2002a).  Whilst this result has been replicated in Koreans (Kim et al. 2003) 
and Japanese (Ban et al. 2006, Mukai et al. 2005) this has not been the case in two large UK 
Caucasian cohorts (Houston et al. 2004, Heward et al. 2004).  The Kozak SNP investigated by 
Tomer et al. was shown not to be associated with HT (Tomer et al. 2002a) and to date, no 
association has been reported with HT. 
 
TSHR 
Autoantibodies targeted against the TSHR can both stimulate and inhibit the thyroid gland with 
the stimulating antibodies leading to hyperthyroidism and the classical clinical features of GD 
(Weetman 2000) (see section 1.4). Using a combination of the TagSNP approach and SNPs 
previously examined in earlier studies, a total of 40 SNPs were examined in two large 
independent AITD case control cohorts; one International cohort with 2030 subjects and one 
exclusively UK with 2427 subjects (Dechairo et al. 2005). Convincing, replicated statistical 
evidence for association of a number of intronic SNPs with GD in the Caucasian population was 
found. A lack of association with HT identified the TSHR as the first GD specific susceptibility 
locus.  
 
Clustering of Autoimmune Diseases 
 The clustering of apparently separate AIDs within one individual has been recognised as 
relatively common, occurring in around 25% of individuals with an existing AID (Mohan and 
Ramesh 2003). The presentation of three or more separate AIDs in one individual has been 
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classified as multiple autoimmune syndrome of which there are three groupings. Type I includes 
myasthenia gravis, thymoma, polymyositis and giant cell myocarditis, Type II includes Sjögren's 
syndrome, RA, primary biliary cirrhosis, scleroderma and AITD and Type III comprises AITD, 
myasthenia gravis and/or thymoma, Sjögren's syndrome, pernicious anaemia, idiopathic 
thrombocytopenic purpura, Addison's disease, insulin-dependent diabetes, vitiligo, autoimmune 
haemolytic anaemia and systemic lupus erythematosus (Humbert and Dupond 1988). The 
clustering of more than one type of AID in families and also in individuals indicates that there 
may be a shared component in the cellular or molecular pathways responsible for the 
manifestation of some AIDs. This theory of a common cellular or molecular pathway is further 
supported by the one common theme in all AIDS, the presence of self reactive antibodies.  
 
When investigating the causal factors of a single disease it is unquestionable that a significant 
result, be it a positive or negative association will further the understanding of that disease. 
Taking note of the theory of common causal components between AIDs it can be seen though 
that a significant finding in one AID may also aid in the future research and understanding of 
other AIDs. Extending this theory further it may also mean that a greater understanding of 
autoimmune disease in general can be gleaned from findings of common or similar genetic and 
environmental causal factors. For this study the HLA gene region is being investigated for 
association with HT, one of the contributing factors in the choice of this region was the previous 
associations seen with not only GD but also with other AIDs (see Chapter 3).The results from this 
study and others like it will in turn go on to provide starting points for the investigation of causal 
genetic factors and pathogenic pathways for other AIDs.  
Chapter 1 Introduction 
 
38 
 
The association of CD40 and TSHR and several other genes (see Table 1.1) with GD but not HT 
does not necessarily imply that they are not common AITD susceptibility loci. As previously 
stated most HT genetic studies have been performed on small cohorts, many of which would 
have been greatly underpowered had they revealed an association. The multifactorial nature of 
HT means that many, if not all genetic causal factors will have a low odd ratio (OR) making them 
almost impossible to reliably detect in small cohorts (see Chapter 2, section 2.8 for the definitions 
and explanations of power and OR). On the other hand these GD only associations may be just as 
they seem and may be GD specific associations not shared by HT. The extreme difference 
between both the symptoms of GD and HT and also between the cellular pathways of 
pathogenesis for these diseases suggests the presence of at least some separate causal factors.  
One genetic region where there is much confusion over whether HT and GD are identical is at the 
HLA class II region. HLA class II molecules play a crucial role in peptide presentation to T cells 
both in the periphery and in thymic selection. For this reason HLA class II has been investigated 
as a candidate gene for a wide range of AIDs (Simmonds and Gough 2004a). HLA class II has 
already been shown to have associations not only in GD (Heward et al. 1998) but also in several 
other autoimmune diseases such as T1D (Todd 1995), systemic lupus erythematosus (SLE) 
(Graham et al. 2002) and RA (Weyand et al. 1992). Due however to the aforementioned use of 
small HT datasets combined with a lack of replication between studies, progress in determining 
HLA class II associations in HT has been much slower. This leaves a degree of uncertainty 
pertaining to whether GD and HT share the same susceptibility loci within this region (see 
Chapter 3).   
Table 1.1: A summary of genes investigated for association with Graves’ disease 
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Locus Reference  
CONSISTENTLY REPLICATED  
CTLA-4 (Furugaki et al. 2004), (Ueda et al. 2003), (Vaidya et al. 1999),   (Yanagawa et al. 1995) 
HLA Class II (Ban et al. 2004), (Chen et al. 2000), (Simmonds et al. 2005c), (Ban et al. 2004), (Wongsurawat et al. 2006)  
PTPN22 (Heward et al. 2007), (Smyth et al. 2004),  (Velaga et al. 2004) 
TSHR (Dechairo et al. 2005),  
AWAITING CONFIRMATION  
CD25 (Brand et al. 2007) 
IDDM2 (Taylor et al. 2006) 
IFIH1 (Sutherland et al. 2007) 
IRF1 (Yang et al. 2005) 
LMP2 (Heward et al. 1999b), (Vives-Pi et al. 1997) 
LMP7 (Heward et al. 1999b), (Vives-Pi et al. 1997) 
PDCD1 (Newby et al. 2007) 
TCR-β (Demaine et al. 1989), (Pickerill et al. 1993), (Zhang et al. 2000) 
TNFα (Nakkuntod et al. 2006a), (Simmonds et al. 2004) 
TPO (Kotani et al. 1986a, Kotani et al. 1986b) , (Ludgate and Vassart 1990), (Pirro et al. 1995) 
UGRP1 (Yang et al. 2005) 
INCONSISTENT FINDINGS   
CD40 (Heward et al. 2004), (Houston et al. 2004), (Jacobson et al. 2005, Jacobson et al. 2007), (Tomer et al. 2002a)  
FCRL3 (Kochi et al. 2005), (Owen et al. 2007), (Simmonds et al. 2005a) 
FOXP3 (Ban et al. 2007), (Owen et al. 2006) 
HLA Class I (Farid et al. 1976), (Grumet et al. 1974), (Huang et al. 2003), (Mather et al. 1980)  
IL-13 (Bednarczuk et al. 2003), (Bednarczuk et al. 2003), (Simmonds et al. 2005b) 
IL-1RN (Blakemore et al. 1995), (Muhlberg et al. 1998) 
IL-4 (Heward et al. 2001), (Yang et al. 2005)  
Tg (Collins et al. 2003, Collins et al. 2004a), (Tomer and Greenberg 2004, Tomer et al. 2002b),  
TNFβ (Nakkuntod et al. 2006b) 
Vitamin D receptor (Ban et al. 2000a, Ban et al. 2000b), (Collins et al. 2004b) , (Ramos-Lopez et al. 2005), (Stefanic et al. 2005) 
X Chromosome (various loci) (Barbesino et al. 1998), (Brix et al. 2005),  (Imrie et al. 2001), (Ozcelik et al. 2006), (Tomer et al. 2003)   
Consistently replicated loci: Associations confirmed by replication 
Loci awaiting conformation:  Preliminary associations found but awaiting replication 
Inconsistent findings: Conflicting results from independent studies  
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For this reason the investigation of HLA class II susceptibility factors in a large HT only cohort is 
important for elucidating the differences between the associated loci in HT and GD in this area. 
In addition the HLA class I region has been associated in several AIDs (see Chapter 4). Hence 
this will also be investigated to determine if components of this region are associated with HT. 
The aim of this thesis therefore is to investigate HLA for association with HT in a large cohort.     
   
Chapter 2 will look at the methods used in preparation for genetic analysis from blood samples. It 
will also look at the specific protocols used in analysis of DNA samples via polymerase chain 
reaction (PCR), allele specific PCR (ASPCR) and TagSNP analysis.  
 
Chapter 3 will look at HLA class II as a causal factor for autoimmune disease and will investigate 
the following aims:  
i. Genotype a large cohort comprising of HT patients and controls at the DRB1, DQA1 
and DQB1 loci in the HLA class II region to determine the predisposing and 
protective genetic factors in the region.  
ii. Analyse the combined DRB1, DQA1, DQB1 haplotypes for association with HT 
iii. Investigate possible phenotype/genotype interactions. 
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Chapter 4 will look at the HLA class I MICA and MICB molecules as causal factors for AID and 
will investigate the following aims: 
i. To genotype a large cohort comprising of HT patients and controls using TagSNPs to 
cover the majority of common polymorphisms with a minor allele frequency of > 20% 
within MICA and MICB. 
To determine the predisposing and protective factors within the MICA and MICB genes via 
statistical analysis of TagSNP frequencies. 
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CHAPTER 2: METHODS AND MATERIALS 
 
Unrelated white Caucasian patients of United Kingdom (UK) origin with no history of thyroid 
surgery, radioiodine therapy or GD were recruited from specialist clinics in Birmingham, 
Bournemouth, Cambridge, Cardiff, Exeter, Leeds, Sheffield, and Newcastle, (UK), as part of the 
UK AITD National collection (see Appendix, 6.1). HT was defined by the presence of 
biochemical hypothyroidism and positive autoantibodies to thyroglobulin (Tg) or Thyroid 
peroxidase (TPO), the presence of lymphocytic infiltrate in a fine-needle aspirate, or the presence 
of a diffuse goitre on physical examination by a thyroid specialist (Manji et al. 2006). Two sets of 
ethnically and gender matched control subjects with no family history of AITD were used in this 
study. Blood samples from control subjects were collected at Blood Transfusion Services 
(Birmingham, UK and Oxford, UK), Birmingham Heartlands Hospital and the Queen Elizabeth 
Hospital (Birmingham, UK) as part of the Birmingham control collection. A set of controls were 
also selected from the 1958 British birth cohort taken from individuals from across the UK who 
were all born within a single week in 1958 (UKDA 2002, CLS 2005).  
2.1 Subjects  
 
The following procedures of blood pelleting, DNA extraction and PicoGreen® were performed 
by myself and other members of the thyroid research group (see Appendix, section 6.1). 
2.2 Blood Pelleting and DNA Extraction 
 
DNA was extracted from 18ml of whole blood collected in two 9ml vacuette tubes (Greiner Bio-
One Ltd, UK) which contained sodium ethylenediaminetetraacetic acid (EDTA) to prevent 
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clotting. The vacuette tubes were stored at 4oC overnight to allow the plasma to separate from the 
erythrocytes. Following this 1ml of plasma was pipetted from each vacuette tube and placed into 
a labelled cryovial (Alpha, UK) and stored at -80oC for potential microsomal and Tg antibody 
testing. The remaining blood samples were each poured into a 50ml falcon tube (TRP, 
Switzerland) and Reagent A (see Appendix, section 6.2) added to the sample to make a total 
volume of 40ml. The samples were inverted several times and then shaken at 170rpm for 4 
minutes on a shaker (Geneflow, UK), then centrifuged at 2400rpm for a further 4 minutes. Once 
the supernatant had been removed, without disturbing the white pellet, 15ml of Reagent A was 
added and the above process repeated to ensure purity of the sample. Once more removing the 
supernatant, 2ml of Reagent B (see Appendix, section 6.2) was added and the tube briefly 
vortexed to re-suspend the pellet. The sample was transferred into a 5ml Cryovial (Alpha, UK) 
and  500µl of Sodium Perchlorate (see Appendix, section 6.2) added to each sample to denature 
the protein. Chloroform (stored at -20oC) was added to further aid protein denaturation and create 
a total volume of 5ml. The Cryovial was inverted 10 times to mix and then centrifuged at 
3000rpm for 5 minutes creating two phases, a supernatant and a protein layer. The supernatant 
was gently removed by pipette and transferred into a fresh Cryovial with care taken not to include 
any of the protein layer. Hundred percent ethanol (-20oC) was then added to precipitate the DNA 
and make up a final volume of 5ml. The presence of precipitated DNA was characterized by a 
white mass within the solution (if no DNA was apparent then the tube was incubated at -80oC for 
30 minutes to aid precipitation). The sample was then centrifuged at 3000rpm for 10 minutes to 
pellet the DNA and the ethanol then removed and discarded. 
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To the pellet, 1ml of 70% ethanol was added; the tube was inverted several times, followed by 
the sample being centrifuged for 5 minutes at 3000rpm. The ethanol was then removed and the 
tube left exposed to air for at least 3 hours to allow the samples to dry (indicated by the pellet 
turning from a milky white to transparent). Once dry, 200µl of T.E. Buffer (see Appendix, 
section 6.2) was added to each sample and the samples incubated at 37oC for 2 hours to allow the 
DNA to re-suspend. 
 
PicoGreen® reagent (Molecular Probes, Eugene, Oregon, USA) was used to quantify the DNA 
samples collected from both HT individuals and control subjects. PicoGreen® is a fluorochrome 
which binds to double stranded DNA (dsDNA) and fluoresces highly when bound. The non-
bound reagent has little fluorescence hence produces little ‘noise’ when samples are processed 
using a standard fluorimeter. PicoGreen® has an excitation maximum at 480nm and an emission 
peak at 520nm.  
2.3 PicoGreen® DNA Quantification 
 
Sigma Calf Thymus DNA (Sigma Aldrich, UK) was re-suspended overnight in 1.0ml of T.E. 
buffer to create a concentration of 1mg/ml. Four µl of re-suspended Calf Thymus DNA and 1246 
µl T.E. buffer provided the starting concentration of 1600ng/ml for a serial dilution. Using T.E. 
buffer as the dilutant, the resulting concentrations of calf thymus DNA were produced to 
complete the standard curve: 800ng/ml, 400ng/ml, 200ng/ml, 100ng/ml, 50ng/ml, 25ng/ml, 
12.5ng/ml, 6.25ng/ml.  
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Two µl of each DNA sample needing to be quantified was diluted in 198 µl T.E. buffer in a 
sterile 0.5 ml microtube (Alpha, UK) in duplicate and left overnight at 4oC to re-suspend.  
 
Using a sterile 96 flat well plate (Alpha, UK) 50 µl of T.E. buffer was added to the first two wells 
in order to serve as controls for the procedure. Fifty µl of each of the standard curve dilutions 
were added to the remaining wells on the first row with duplicates added to the second row. Five 
µl of each of the duplicated DNA samples were added to the remaining wells on the plate, 
allowing 36 samples to be analysed in total(see Figure 2.1).   
 
1194 µl T.E. buffer was added to 6 µl of thawed PicoGreen® reagent in an amber microtube 
(Alpha, UK) to create PicoGreen solution A. To create PicoGreen solution B 7580 µl T.E. Buffer 
was added to 20 µl PicoGreen® reagent. As the PicoGreen compound displays light sensitivity 
all solutions containing the compound were prepared and stored in amber/foil covered vessels. 
Fifty µl of PicoGreen solution A was added to each of the standards and T.E. controls whilst 95 
µl of PicoGreen solution B was added to each of the DNA samples. The plate was read 
immediately on a Wallac Victor 3™ Multilabel counter (Applied Biosystems, UK) using 
standard fluorescein wavelengths, excitation 480nm and emission 520nm.  
  
  
Figure 2.1: Layout of the 96 flat well plate for the Picogreen® protocol 
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
             A CONTROL 800ng/ml 400ng/ml 200ng/ml 100ng/ml 50ng/ml 25ng/ml 12.5ng/ml 6.25ng/ml EMPTY EMPTY EMPTY 
B CONTROL 800ng/ml 400ng/ml 200ng/ml 100ng/ml 50ng/ml 25ng/ml 12.5ng/ml 6.25ng/ml EMPTY EMPTY EMPTY 
C Sample 1 Sample1 Sample 2 Sample 2 Sample 3 Sample 3 Sample 4 Sample 4 Sample 5 Sample 5 Sample 6 Sample 6 
. . . . . . . . . . . . . 
. . . . . . . . . . . . . 
. . . . . . . . . . . . . 
. . . . . . . . . . . . . 
H Sample 31 Sample 31 Sample 32 Sample 32 Sample 33 Sample 33 Sample 34 Sample 34 Sample 35 Sample 35 Sample 36 Sample 36 
 
 
 
 
Wells A1 and B1 show blank controls containing 50 µl of T.E. buffer. Wells A2-A10 and B2-B10 show concentrations of the 
serial dilution of calf thymus DNA forming the standard curve. Rows C through H show DNA samples in duplicate. 
Chapter 2  Methods and Materials 
 
47 
 
The standard dilutions formed the basis of a standard curve against which the DNA samples can 
be compared. Repeat tests were performed on any 2 samples for which there was a difference of 
greater than 20%. Using the concentrations determined each DNA stock sample was then diluted 
in T.E. Buffer to a concentration of 100ng/ul and then to 20ng/ul to create a uniform DNA 
dilution for all samples. The 20ng/ul samples prepared were used in the MICA and MICB study 
(see chapter 4). Neat DNA was used in the HLA study (see chapter 3) 
 
The PCR technique for DNA amplification was used for both the HLA and MICA and MICB  
studies. The following gives an overview of the general principles of PCR whilst the exact 
methods for each study can be found later in Chapter 3 and Chapter 4. 
2.4 Polymerase chain reaction (PCR) 
 
The PCR technique is designed to amplify a section of DNA. Oligonucleotides are designed 
around the region of interest which act as primers in the reaction. The two oligonucleotides are 
different in sequence and are complimentary to the known areas of sequence either side of the 
desired region for amplification. The PCR reaction also requires Taq polymerase, magnesium 
chloride and the presence of deoxyribonucleoside triphosphates (dNTPs) which act as free base 
pairings for the forming strands. 
 
The amplification of the DNA is achieved by first denaturing the template double stranded DNA 
in the presence of the primers. The cooling step following this allows annealing of the primers to 
their target sequences on the template DNA. The Taq polymerase then allows the extension of the 
primers to form complementary DNA strands across the length of the desired region utilising the 
Chapter 2  Methods and Materials 
 
48 
 
free dNTPs available. This cycle of denaturing and annealing is repeated numerous times 
allowing the strands formed from the last cycle to serve as the templates for the following cycle. 
With each cycle the quantity of the target DNA is doubled. (see Figure 2.2)  
 
Oligonucleotide primers 
To avoid unnecessary amplification of unwanted areas the primers must only anneal to the 
flanking region and hence a sequence unique to that region must be chosen as the template for the 
primers. The two sequences should exhibit minimal complementarity to reduce the likelihood of 
the formation of primer dimers (Fuchs and Podda 2005). Ideally the primers should be between 
20-30 bases in length. A high CG content requires a high annealing temperature, so it is 
preferable to use a sequence with a low CG content (around 50% or less) for the primers. CG 
base pairs are more stable than AT pairs due to the triple hydrogen bond between the nucleotides 
(as opposed to the double bond in AT pairs). Therefore high GC content, causes a high melting 
temperature to be required (Ausubel et al. 2003, Gray and Honigberg 2001). Similarly the CG 
content of the two primers should be similar so that the annealing stage occurs at a similar 
temperature. 
 
Taq Polymerase 
PCR is catalysed by Taq DNA polymerase a form of polymerase originally isolated from the 
bacterium Thermus aquaticus. T.aquaticus reside in hot springs, hence the polymerase derived 
from these bacteria is able to withstand the unusually high temperatures (of up to 95oC) required 
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Figure 2.2: cycle of DNA replication via the polymerase chain reaction. 
 
 
 
 
 
 
1. Taq Polymerase allows the extension of the primers to from two new complimentary strands 
2. The cycle repeats using both the original dsDNA as a template for the new strands in addition 
to the 2 short sections of DNA formed from the first cycle. 
3. The cycle continues, with each repetition the short DNA sections from the previous cycle are 
used as templates in the new cycle. This allows for exponential growth in the number of strands 
formed in each cycle. 
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for PCR protocol. The amount of Taq polymerase used in each reaction must be carefully 
determined. Increasing the volume used increases the efficiency of the reaction, however this can 
also increase the frequency of non-specific primer binding. Most common forms of Taq 
polymerase used in PCR reactions do not have 3’-5’ proof reading ability.  
 
dNTP concentration 
The dNTPs present in the PCR reaction serve as the raw material from which the new DNA 
strands are formed. If the concentration is too low then there is not enough raw material to 
complete the number of cycles needed. Increasing the concentration increases the efficiency of 
the reaction; however above a certain point increasing the concentration may cause the error rate 
of the Taq polymerase to increase. An increased concentration of dNTPs will also affect the 
MgCl2 concentration required as dNTPs chelate magnesium. For 12.5µg of synthesised DNA, 
200µM of each dNTP allows half of the dNTPs to become incorporated (Ausubel 2001).   
 
Buffer and Magnesium chloride 
PCR reactions require a buffer to be used to maintain the pH at a level in which Taq polymerase 
can function. Magnesium chloride is used as a source of magnesium in the PCR reaction. 
Magnesium binds to single nucleotides forming a substrate which allows Taq polymerase to bind. 
The optimal MgCl2 concentration must be determined for each primer pair used in PCR reactions 
separately as the concentration required is dependent on the DNA sequence. The optimal 
concentration is determined via titration and is normally found to be within the range of 0.5mM – 
4.0mM. Concentrations below this range do not allow the PCR product to be visualised whilst 
concentrations above the stated range may result in non-specific banding.  
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Purity of PCR components 
Due to the repetitive nature of the PCR cycling a small anomaly can become greatly magnified. If 
DNA foreign to the desired sample is present or a mutagenic component is introduced then the 
final PCR product will show anomalies. To minimise this the reagents used in the PCR reaction 
must be free from contamination. The reagents mentioned previously must be of high quality and 
purity and in addition MilliQ water (NANOpure DiamondTM, UK) is used to dilute where 
required as MilliQ water contains lower levels of DNase, RNase, microorganisms and other 
contaminants than normal distilled water. To test for DNA contamination at least one well on 
each plate is left blank, containing only the reagents but none of the sample DNA. Any 
amplification seen in this well will indicate if a foreign source of DNA in present in any of the 
reagents used or has been transferred onto the plate from equipment used during the PCR 
protocol.  
 
Thermal cycling 
Two different PCR thermal cycling methods were used in this study. They both however follow 
the same basic pattern with the main difference being an additional primary step for the MICA 
and MICB thermal cycling protocol. For this the temperature was first raised to 50oC for a period 
of 2 minutes to facilitate activation of the Taq polymerase. The following steps of denaturation 
and annealing were common to both studies. 
 
For the denaturation step the temperature is kept within the range of 93 oC to 96oC. This range 
allows for separation of the DNA double strand whilst conferring little or no decrease on the 
activity of the Taq polymerase. The exact temperature used is again dependent on the CG content 
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of the template with higher CG content requiring higher temperatures. This is a rapid stage and 
does not normally exceed 1 minute.  
 
The temperature is lowered for the annealing stage (in this thesis temperatures ranging between  
55oC  and 70oC were used). The temperature must be such that the DNA template remains in a 
semi-denatured state whilst allowing the primers to anneal stably to the template and 55oC is the 
average optimal temperature for this. However this process is once again dependent on CG 
content. Primers with a CG content which is either higher or lower than 50% may require 
annealing temperatures of either higher or lower than 55oC respectively. Using non-optimal 
temperatures in this stage increases the occurrence of non-specific primer annealing.  
 
In these studies extension temperatures of between 60oC and 72oC were used. The optimal 
working temperature for the Taq polymerase used is 75oC, hence using temperatures around this 
region will allow for efficient use of Taq polymerase whilst allowing the primers to remain 
attached to the template DNA. The length of the DNA section which is required to be amplified 
affects the length of time needed for the extension procedure and in these studies times of 25 
seconds to 90 seconds were used.  
 
Conventionally in PCR reactions the annealing and extension stages are separate with the 
annealing stage being at a lower temperature than that of the extension. However in the MICA 
and MICB study the primers were designed by Applied Biosystems UK to anneal at a higher 
temperature, meaning that a separate stage is not required. As well as making the PCR much 
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quicker the samples are at less risk of contamination because the temperature is kept higher at 
this stage. 
 
ASPCR uses two or more primers which are able to discriminate between the different alleles of 
a given locus. The primers are designed to be able to discriminate between the different alleles by 
insertions, deletions, single base polymorphisms or other small base pair changes found in the 
DNA region of interest. Each primer will therefore only bind to the single strand of DNA for 
which it is complementary (see Figure 2.3).    
2.5 Allele Specific PCR(ASPCR) 
 
In each reaction control primers which amplify a DNA region outside the region of interest are 
used. These primers amplify products of different sizes to those produced from within the region 
of interest. Presence of the control bands in a PCR reaction ensures the PCR reaction was 
successful if allele bands are absent from the sample.  
 
Agarose gel electrophoresis was used to visualise PCR products in the HLA class II study (See 
Chapter 3). This method allows the DNA fragments to be separated by size and charge. A solid 
agarose gel is created, the concentration of which is proportional to the size of the products to be 
analysed. These gels are placed in gel tanks and covered with buffer. The DNA samples are 
loaded through the layer of buffer into wells cut into the gel. A general outline of the method is 
given below with further details of the volumes and measure used given later in Chapter 3. 
2.6 Agarose gel electrophoresis 
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Figure 2.3: Primers used in PCR reactions 
 
 
 
 
 
 
 
 
 
1. In a PCR reaction primers are designed as complimentary to the forward or reverse strand as 
appropriate 
2. In an ASPCR reaction the primers are designed similarly but 2 separate primers are used for 
each reaction, each containing a different base at the SNP locus. 
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A fixed volume of electrophoresis buffer (0.5% x TBE; see Appendix, section 6.2) was prepared 
for both the creation of the gels and to be used as buffer in the gel tanks. Five grams of 
electrophoresis-grade agarose (Sigma, UK) was added to 500ml 0.5% TBE to create the gels. 
This was heated using a hotplate and magnetic stirrer (Geneflow, UK). The gel was heated until 
the agarose powder had fully dissolved, at which point the solution was allowed to cool. Once the 
solution had cooled to below 55oC an appropriate amount of ethidium bromide (Sigma, UK) was 
added to facilitate later visualisation. A casting tray with gel combs and casting gates was 
prepared and the gel solution poured into it. Once the gel had hardened the casting gates and gel 
combs were removed and the gel still in the casting tray placed into a gel tank. A volume of TBE 
(see Appendix, section 6.2) was added to the gel tank so as to completely cover the gel and again 
an appropriate volume of ethidium bromide was added to this. The DNA samples were mixed 
with loading buffer (see Appendix, section 6.2) and loaded into the wells in the gel. The gel was 
then run at an appropriate voltage for a set amount of time to allow a current to be created across 
the length of the gel and the DNA fragments to separate and move down the gel. When finished 
the gel was removed and visualised under UV light with a photograph taken as a permanent 
record of the results.  
 
The allelic discrimination in the MICA and MICB study was performed using single nucleotide 
polymorphisms (SNPs). SNPs are loci where the DNA differs by a single base and the rare allele 
occurs at a frequency ≥ 1% in the general population (Pasternak 2005). Genotyping data for the 
MICA and MICB gene regions was obtained from the International Haplotype Mapping Project 
web site [www.hapmap.org]. The data was then incorporated into the Haploview program 
2.7 Tag SNPs 
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[http://www.broad.mit.edu/mpg/haploview/] which allowed the number of SNPs with an allelic 
frequency greater than 5% to be calculated. The tagger function on the Haploview program was 
used to calculate the linkage disequilibrium (LD) between the selected SNPs and determine 
groups of SNPs which were in strong LD with each other. For each group a tag SNP was chosen 
which was in strong LD (D’>0.80) with those which it tagged (Gabriel et al. 2002)  (see section 
2.8.4 Linkage Disequilibrium for further information) 
 
Assays 
Pre-validated assays were purchased from Applied Biosystems ‘assay on demand’ service 
[www.appliedbiosystems.com] for 8 SNPs. For the remaining 7 SNPs no assay had previously 
been designed. For these SNPs sequencing data surrounding the SNP of interest was obtained 
from the NCBI SNP web site [www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Snp] was used to 
design an appropriate assay and the sequences were then submitted to Applied Biosystems 
‘assays by design’ service [www.appliedbiosystems.com].  
 
Taqman Probes 
All assays contained two probes; VIC and FAM to detect alleles 1 and 2 respectively of the SNP 
being assayed. Initially the fluorescing portion of the probe, either VIC or FAM, is prevented 
from fluorescing by a non-fluorescent quencher (NFQ). As the forming strand reaches the 
location of the probe the fluorescent portion is displaced hence it is no longer attached to the 
NFQ and is seen to fluoresce (see Figure 2.4). The probe will bind to the DNA present in   
accordance with the allele exhibited; in a heterozygous sample VIC and FAM will both bind, in a 
homozygous sample only one type of probe will bind. The probes fluoresce with different 
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wavelengths enabling the sample to be read using the ABI7900 prism (Applied Biosystems, UK). 
 
2.8.1 Power calculations 
2.8 Statistical analysis 
Association studies have been commonly seen as a useful method for detecting small genetic 
contributions to disease. Unfortunately association studies also commonly show a high degree of 
variation in results between replication studies. As a means of combating this problem power 
calculations can be used to define the probability that a test can identify a given difference in the 
population frequency of a marker between cases and control subjects in a given dataset as being 
significant (P=0.05) and is based on a null hypothesis (Barcikowski 1981, Risch and Merikangas 
1996, Lalouel and Rohrwasser 2002). Power calculations can be used to determine the probability 
that a false null hypothesis will be rejected. It is assumed that any test with a statistical outcome 
of P< 0.05 indicates that the outcome was not by chance or coincidence. Conventionally a power 
of >80% is accepted (see Chapter 1, section 1.6.1 for further discussion). 
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Figure 2.4: Probe binding and fluorescence 
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2.8.2 Case control analysis 
All analysis of case control data was performed using the χ2 test or for small numbers the Fisher’s 
exact probability test.  
 
The χ2 test was used in conjunction with a 2 x 2 contingency table as shown below. 
 
 Positive for marker Negative for marker 
Hashimoto’s thyroiditis patients a b 
Control subjects c d 
 
 
  
The χ2 value was calculated and probabilities assigned (see Appendix, section 6.3 for χ2 
calculation). All χ2 calculations were performed using Excel (Microsoft® Excel, © 1985-2003 
Microsoft Corporation). 
 
The Fishers exact probability test was used when any number in the contingency table had a 
value of 10 or less and all calculations were performed using the MINITAB statistical package 
(MINITAB Release 14.1 © 1972–2003, Minitab Inc, USA.) (see Appendix, section 6.3 for 
Fishers exact probability test calculation). 
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All P values are presented as uncorrected and P<0.05 was considered significant. All P values 
presented have not been corrected for multiple tests. Statistical correlations are not commonly 
presented for the methods of genetic analysis use in this thesis.  
 
For any result found to be significantly associated with disease the odds ratio (OR) and 95% 
confidence interval (95% CI) was calculated using the method of Woolf with Haldane’s 
modification for small numbers (Woolf 1955) (see Appendix, section 6.3 for OR and 95% CI 
calculations). The OR test is a form of the χ2 test where the probability of an individual with the 
major allele exhibiting HT is compared to the probability of an individual with the minor allele 
exhibiting HT.  The 95% CI calculation is a measure of variation. It implies that although the OR 
calculated may be incorrect there is only a 5% chance that the confidence limits generated do not 
contain the true OR (BMJ 2006). If the OR is greater than 1 and the lower boundary of the 95% 
CI is greater than 1 then there is a significant risk of exhibiting the disease phenotype if the 
mutant allele is present (Shephard 2005). 
 
2.8.3 Hardy Weinberg Equilibrium (HWE) 
The law of HWE proposes that polymorphisms become stable in the general population after one 
generation of random mating. HWE calculations were performed for all successfully genotyped 
Hashimoto’s thyroiditis patients and control subjects in both studies using a program based on 
one designed by Dr. Heather Cordell, University of Cambridge, UK.  
 
  
Chapter 2  Methods and Materials 
 
61 
 
2.8.4 Linkage Disequilibrium (LD) 
The global D prime (D’) calculation (Hedrick 1987) may be used to calculate the LD between 
two given genetic markers. LD gives a measure of the likelihood that two markers will be 
inherited as a haplotype. The calculation compares the probability at which the markers would be 
inherited as a pair if linked compared to the rate at which they would be inherited if combined 
randomly. A strong LD is often indicative of a physically close relationship between the two 
markers. A D’ of 1 is complete LD, a D’ greater than 0.8 is considered to be strong LD, a D’ 
between 0.2 and 0.8 is incomplete LD and less than 0.2 is considered negligible (Ardlie et al. 
2002). For the Tag SNP study SNPs which displayed LD greater than 0.8 were selected.  
 
 
Chapter 3 HLA class II 
 
62 
 
CHAPTER 3: HLA CLASS II 
 
The HLA region is located at chromosome 6p21-23 (NLM 2008). The region consists of a 
group of genes primarily concerned with humoral and cell mediated immune response. Within 
this region three major groupings are apparent, HLA class I, HLA class II and HLA class III 
(see Figure 3.1 for HLA class arrangement). The HLA class I and class II gene regions 
encode membrane bound glycoproteins which display structural and functional similarity. In 
contrast the HLA class III region genes encode proteins which differ in both structure and 
function to the class I and class II loci. In addition the HLA class III genes also encode a 
variety of other secreted products. The class I region spans approximately 2Mb and contains 
the classical class I genes HLA-A, HLA-B and HLA-C and non-classical class I genes 
including HLA-E, HLA- F, HLA-G, HFE, HLA-J, HLA-X, MICA, MICB, MICC, MICD and 
MICE. (see chapter 4 for further discussion of HLA Class I). The class III region encodes 
various components of the innate and adaptive immune response (see Chapter 1, section 1.2 
for further discussion of the immune response) including the complement components C4, C2 
which are involved in the mannose-binding lectin pathway and factor B which is involved in 
the alternative complement pathway. Several inflammatory cytokines including tumour 
necrosis factor α (TNFα), lymphotoxin α, heat shock proteins and several other products are 
also encoded in this region.  
3.1 Introduction 
 
Whilst most genetic studies in autoimmune disease has concentrated on the role of HLA class 
I and class II regions in disease, some work has explored association of the class III genes 
with an association of TNFα with GD (Simmonds et al. 2004) and a tentative association with  
  
Figure 3.1: Schematic of the HLA gene region 
 
 
 
 
 
C: Complement 
HSP: Heat shock protein 
TNF: Tumor necrosis factor 
MIC: MHC class I chain related 
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HT (Chen et al. 2006) being demonstrated. For this chapter the role of HLA class II as a 
susceptibility locus for HT is discussed.  
 
The HLA Class II gene region spans approximately 1 x 106 bp and contains genes encoding 
polymorphic, heterodimeric, bound glycoproteins mainly expressed on antigen presenting 
cells such as macrophages, dendritic cells and B cells in addition to many other molecules. 
The best characterised of these genes, DP, DQ and DR  encode proteins that display processed 
antigenic peptides for  recognition by T helper cells (TH cells) (see Figure 3.2).  
3.1.2 HLA Class II 
 
The HLA Class II molecules are comprised of an α and β chain encoded by two separate 
genes. The α and β chain are indentified by having a letter A or B after the molecule being 
encoded for example the DR alpha chain is called DRA and the DR beta chain is called DRB. 
Both the α and β genes contain a leader exon, α1 or β1 exon, α2 or β2 exon, a transmembrane 
exon and one or more cytoplasmic exons. The DR and DQ chains all have similar 
substructures.In each the first exon encodes the signal sequence, the second the α1 or β1 
domain, the third the α2 or β2 domain, the fourth the transmembrane domain and part of the 
cytoplasmic domain and the fifth again part of the cytoplasmic domain. DRA, DRB and DQA 
also share the encoding of the cytoplasmic domain over a sixth exon whilst DQB completes 
the cytoplasmic domain and terminates at exon 5 (Goldsby and Goldsby 2003).   
 
The DQA1, DQB1 and DRB1-9 (specifically DRB1) regions are all highly polymorphic. 
DQA1 contains 6 loci and 22 alleles, DQB1 5 loci and 46 alleles and DRB1 13 loci and 335 
alleles (http://www.ebi.ac.uk/imgt/hla/links.html). This makes these regions ideal for this
  
Figure 3.2: schematic of HLA class II gene region 
 
 
 
 
PSMB: proteasome subunit beta-type 
TAP: transporter associated with antigen processing
Chapter 3 HLA class II 
 
66 
 
study as the numerous polymorphisms allow for a high density scan of this region. These 
polymorphisms are reflected in the nomenclature, for example, DRB1*04 denotes that DRB1 
is the beta chain in question and that the locus is 04. The DRA region however contains 
relatively few polymorphisms and for this reason was not investigated 
(http://www.ebi.ac.uk/imgt/hla/links.html).  
 
Structure and function of the HLA Class II molecules 
The HLA Class II molecules are comprised of two polypeptide chains, a 33kDa α chain and a 
28kDa β chain. These two chains are linked by non-covalent interactions to form a membrane 
bou nd  glycop ro tein. Each chain  con sists of two external d omain s α1 , α2  or β1 , β2 , a 
transmembrane segment and a cytoplasmic segment. (see Figure 3.3). The outermost portions 
of the molecule, the α1 and β1 segments, form the antigen binding cleft  
 
The bound peptides originate via the exogenous pathway from antigen presenting cells 
(APCs) including macrophages, immature dendritic cells, B cells and CD4+ T cells. 
Membrane bound proteins and other external proteins are internalised by APCs via 
phagocytosis, endocytosis or a combination of both. Internalised antigen then enters the 
endolytic processing pathway. The exogenous antigen passes through three compartments, 
early endosomes, endolysosomes and finally lysosomes. Each compartment contains 
hydrolytic enzymes and is more acidic than the last at around pH 6.0-6.5, pH 5.0-6.0 and pH 
4.5-5.0, respectively and is degraded into peptide. This results in oligopeptides of around 13-
18 residues in length which are optimal for binding by HLA class II molecules.  
  
Figure 3.3: HLA class I and class II molecule structures 
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HLA class II molecules are synthesised in the rough endoplasmic reticulum. Once synthesised 
they are immediately able to bind peptides. To prevent unwanted peptides or unfolded 
proteins or endogenous antigens from attaching to the binding cleft the HLA class II invariant 
chain (Ii) binds in its place. By association with Ii the HLA class II molecules can then move 
to a low pH endosomal compartment to allow peptide binding to occur. For peptides to bind 
in the HLA Class II binding cleft the Ii must first be removed. This is done in a series of steps 
where the Ii is cleaved into shorter fragments. The remaining fragment, the HLA class II 
associated invariant chain peptide (CLIP), must either be displaced or must dissociate to allow 
binding of other peptides to occur. Once a peptide has bound the HLA class II molecule then 
moves to the cell surface for presentation to CD4+ T cells and Tregs as part of peripheral 
tolerance. HLA class II molecules also present antigens to CD4+8+ thymocytes during 
positive selection during central tolerance (see Chapter 1, section 1.2). If however no peptide 
binds then the molecule becomes unstable and degrades in the acidic environment of the 
endosome.  
 
As previously stated the majority of studies investigating the genetic causal factors of AITD 
have focused primarily on GD. This has been in part due to the previous assumption that the 
causal factors for HT were common to GD also. The early results obtained for HT were 
pertinent due to the findings in HLA class II association studies in GD. One example of this 
can be seen in the common AITD predisposing loci found in genome wide scans (see Chapter 
1, section 1.6.1). Due to the vast amount of work performed concerning the association of the 
HLA region with GD it is important to investigate these findings in addition to the 
comparatively few studies performed on HT cohorts.  
3.2 Association of HLA with Autoimmune Thyroid disease 
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Graves’ disease 
Early studies had shown association of the DR3 haplotype (DRB1*03-DQB1*02-DQA1*05 ) 
and its component alleles with GD (Dahlberg et al. 1981, Farid et al. 1980) The association of 
DR3 with GD has been validated with consistent reports finding association of the DR3 
haplotype with GD in studies using large cohorts (Boehm et al. 1992, Heward et al. 1998, 
Simmonds et al. 2005, Mangklabruks et al. 1991, Badenhoop et al. 1992)..  
 
The nature of the association of the DR3 haplotype with GD has been brought into question. 
It has been proposed that DQA1*0501 was associated with GD independently of the DR3 
haplotype as a whole. This was based on increased prevalence in GD patients in a study of 
USA Caucasian subjects (Yanagawa et al. 1993). The question of whether the DR3 haplotype 
is associated with GD as a result of strong LD between the included alleles or whether the 
haplotype as a whole is associated has attempted to be answered by several studies (Cuddihy 
and Bahn 1996, Hunt et al. 2001, Yanagawa et al. 1994, Maciel et al. 2001, Heward et al. 
1998). The work performed by Heward et al. (Heward et al. 1998) in one such study was 
furthered by regression mapping of the HLA region in a study performed by the same group 
(Simmonds et al. 2005). Using stepwise logistic-regression DQB1 did not improve allele 
based models containing either DRB1 (P=0.154) or DQA1 (P=0.04). When an allele based 
model containing DQB1 was used however both DRB1 (P=1.88×10-8) and DQA1 (P=3.99×10-
8) improved the model. This indicated that the main associated locus within the HLA class II 
region was not contained within the DRB1 gene. It could not be ruled out however whether 
the main etiological variant within the HLA class II region was contained in DRB1 or DQA1 
(Simmonds et al. 2005). 
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Some moves have been made to further narrow the associated locus within the DRB1 region 
of HLA class II. Two studies have shown association of Arginine at position β74 of the DRB1 
chain (Ban et al. 2004, Simmonds et al. 2006). Using stepwise logistic regression this result 
was further examined in comparison to other amino acids in the DRB1 chain with the finding 
that β74 remained the most strongly associated, although a series of other amino acid 
positions were also found to be associated (β10, β11, β12, β13, β14, β25, β26, β30, β32, β47, 
β58 and β71) (Simmonds et al. 2005). Whilst this association was reported in both the studies 
by Ban et al. (Ban et al. 2004) and Simmonds et al. (Simmonds et al. 2006) the relation of the 
finding to the previously reported DR3 association is still in question. Although the former 
study found that the β74 association was independent of the DR3 association the latter study 
could not confirm this.  
 
Other associations of HLA class II have also been shown with GD, DRB1*07 and the DR7 
haplotype (DRB1*07-DQB1*02-DQA1*02) have been shown to have a protective effect 
against onset of GD (Simmonds et al. 2005). DRB1*08 has also been shown to be associated 
with GD in a North American Caucasian cohort (P<0.01, OR=3.2) (Chen et al. 1999).The 
study showed however that DRB1*08 was only significantly associated with early onset GD 
(P=0.001, OR=5.0) and no significant association with late onset GD was reported. It should 
be noted that by splitting up the cohort of 92 GD patients only 30 were classified as affected 
by early onset GD. This is an incredibly small dataset on which to perform age of onset 
correlations and requires confirmation in a larger cohort. 
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Hashimoto’s Thyroiditis  
As with many genetic studies in HT there have been few performed concerning HLA Class II 
associations. Those which have been performed have often been on small numbers using 
cohorts of under 500 HT cases and 500 controls. In early association studies using serologic 
markers DR3 and DR5 haplotypes were shown to be associated, although with differing 
results. In 1978 a study using a cohort of 262 Canadian Caucasian individuals (127 cases, 135 
controls) showed the DRw3 (now known as DR3) haplotype to be associated with HT (RR = 
3.5) (Moens et al. 1978). In 1980 a study using a cohort of 199 Austrian Caucasian 
individuals (39 cases, 160 controls) showed association of DR5 (RR = 3.2) (Weissel et al. 
1980). In 1981 these first two studies were seemingly supported by the findings of a Canadian 
study where both DR3 and DR5 were found to be associated in a Caucasian cohort of 120 
individuals (40 cases and 80 controls) (Farid et al. 1981).  Again in 1987 an association of 
DR3 with a cohort of 68 Eastern Hungarian HT patients was observed (Stenszky et al. 1987). 
In 1991 using a UK Caucasian dataset of 186 (86 cases and 100 controls) DR3 (OR = 3.3) and 
DQw2 were found to be associated (Tandon et al. 1991). The association of DQw2 in this 
study may not be an independent risk factor as it is known to be in strong LD with the DR3 
haplotype; hence this may be as a result of the DR3 association. 
 
 Following these early results studies began to use larger cohorts in an attempt to provide 
more accurate results. In 2001 two larger Caucasian studies attempted to provide insight into 
the HLA Class II association with HT. In a UK Caucasian cohort of 344 individuals an 
association of HLA-DRB1*03 (P=0.02, OR=1.9) with HT was observed (Hunt et al. 2001). In 
the same year an Italian study performed by Petrone et al. using a Caucasian cohort of 427 
(126 HT patience and 301 controls) showed association of DRB1*04-DQB1*0301 with HT 
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(Petrone et al. 2001). Although these later studies used much larger cohorts the disparity in 
the results may indicate that the cohorts were still too small to detect associations reliably.  
 
In addition to the tentative associations proposed for DR3 and DR5 haplotypes, other alleles 
and haplotypes have been investigated. In 1986 Farid  et al. found association of the DR4 
haplotype  (HLA-DRB1*04, HLA-DQA1*03, HLA-DQB1*03) in a small cohort of 192 (52 
cases, 140 controls) (OR = 3.1) (Farid and Thompson 1986). This finding was replicated in 
Caucasians in Petrone’s 2001 study as previously mentioned (Petrone et al. 2001). A study 
utilising a Japanese cohort of 388 individuals with 71 HT patients and 317 controls showed 
associations of the DR4 haplotype (RR = 4.5) (Wan et al. 1995). However, due to the 
differing genetic backgrounds seen in different ancestral geographical regions, these results 
may not be comparable to those obtained in studies using Caucasian cohorts. 
  
In addition to these findings Badenhoop et al. found association of DQA1*0201/*0301 
heterozygotes and also DQA1*0301/DQB1*0301 (RR = 4.7) with HT (Badenhoop et al. 
1990). Also a protective effect has also been proposed by Tamai et al. in a Japanese cohort of 
105 HT patients and 317 control subjects for DQA1*0102 (RR = 0.3) and DQB1*0602 (RR = 
0.1). This, however, is yet to be replicated.  
.  
There have been many other studies which have investigated the associations of HLA Class II 
with HT (see Table 3.1). However the cohorts used in these were very small, often with the 
entire dataset being under 100 hence the results of these studies are not considered in detail.  
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Table 3.1: Past associations of HLA class II with HT 
 
 
 
 
 
Author Cases Controls Total 
cohort 
Nationality Allele/haplotype OR/ RR 
(Badenhoop et al. 
1990) 
64 98 162 - DQA1*0201/*0301 
heterozygotes 
- - 
      DQA1*0301/DQB1*0301 - 4.7 
(Hunt et al. 2001) 77 267 344 UK* DRB1*03 - - 
(Moens et al. 1978) 127 135 262 Canadian* DR3 - 3.5 
(Santamaria et al. 
1994) 
17 71 
- N. European DQB1*0201 
- - 
(Shi et al. 1992) 46 50 96 Caucasian DQA*0301 - - 
  32 50 82  DQB*0201 - - 
(Stenszky et al. 
1987) 
68 - - Hungarian DR3 3.3 - 
(Tamai et al. 1994) 105 317 - Japanese DQA1*0102 (protective) - 0.3 
     DQB1*0602 (protective) - 0.1 
(Tandon et al. 1991) 86 100 186 English* DR3,DQA1*0501/DQB1*0201 - - 
(Wan et al. 1995) 71 317 388 Japanese DRB1*0403 - 3.2 
     DR4*0101 - 4.5 
(Weissel et al. 1980) 39 160 199 Austrian* DR5 - 3.2 
 
 
 
*denotes that the cohort was Caucasian 
- denotes that no data was given 
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This proposed study aims to compare HLA class II associations found in GD patients with 
class II associations in HT patients. The HT patients used in this study were recruited as part 
of the UK AITD national collection. These patients were recruited from the same geographic 
regions as GD patients in the UK national collection. In addition the same control cohort was 
used for this study as several previous GD association studies. This provides a basis for a 
direct comparison of the HT and GD associated loci within the HLA class II region.  
 
 
The primary aim of this study was to: 
3.3 Aims of Chapter 3 
i)  Genotype a large cohort comprising of HT patients and controls at the DRB1, 
DQA1 and DQB1 loci in the HLA class II region to determine the predisposing 
and protective genetic factors in the region.  
ii) Analyse the combined DRB1, DQA1, DQB1 haplotypes for association with 
HT 
iii) Investigate possible phenotype/genotype interactions. 
 
 
3.4 HLA methods  
As described in Chapter 2, section 2.1. In total, DNA was obtained from 640 HT patients and 
621 control subjects taken from the control set for the Birmingham control collection. The 
621 control subjects used in this study had all been previously genotyped (Simmonds et al. 
2005) 
3.4.1 Subjects 
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The HLA-DRB1, DQB1 and DQA1 regions were amplified using the phototyping method of 
allele specific PCR (ASPCR) as previously published (Bunce et al. 1995) (see Appendix, 
section 6.4 for primers). To screen these three regions, 48 ASPCR reactions were performed.  
For each of the 48 ASPCRs a given allele or set of alleles for the HLA-DRB1, DQB1 and 
DQA1 loci were amplified. A set of control primers (which amplified a 796bp fragment from 
the third intron of HLA-DRB1) were also included in each reaction to ensure that the PCR 
had not failed and that non-amplification of allelic bands was due to their absence.  
3.4.2 Genotyping 
 
Primers 
All primer sequences and working primer concentrations for HLA-DRB1, -DQA1 and -DQB1 
were obtained from previous work by Bunce et al (Bunce et al. 1995) (see Appendix, section 
6.4). All primers were obtained from Sigma Genosys, UK. The primers were reconstituted 
with 1 ml of TE Buffer to stabilise the primers. The primers were then diluted to their 
working concentration at a final volume of 1ml using the following formulae: 
Primer amount (μM) = Primer OD x 100 / (1.5(A) + 0.71(C) + 1.2 (G) + 0.84(T)) 
Primer amount (μl/ml) = required working primer conc. x 1000 / primer amount 
Where A C G T refer to the frequency of each base in the primer sequence.  
All primer working concentrations were frozen at -20oC until required.  
 
Five μl of each of the prepared primer solutions were pipetted into 48 wells of a 96 well plate 
(Greiner, UK) with two sets of ASPCR per 96 well plate. Ten μl of mineral oil (Sigma, UK) 
was added to each well to cover the primer and reduce evaporation in the later PCR process. 
The prepared 96 well plates were frozen at -20oC until required.  
Chapter 3 HLA class II 
 
76 
 
PCR 
For each patient and control sample a solution of 300 μl TDMH (see Appendix, section 6.2) 
169 μl Millq water, 9 μl DNA sample and 2.25 μl Taq (Bioline, UK) was produced, then 
briefly vortexed before 8 μl of the resulting solution was added to each of the 48 wells on the 
PCR plate containing the ASPCR primers. The plate was then sealed with a plastic sealer 
(Griener, UK), and centrifuged at 1000rpm for 1 minute. The plates were then run on M J 
Research PTC-225 Peltier Thermal cycler machine (Genetic Research Instrumentation, UK) 
using the following program: 
60 seconds denaturation – 96oC 
5 cycles: 20 seconds – 96 oC 
  45 seconds – 70 oC 
  25 seconds – 72 oC 
21 cycles: 25 seconds – 96 oC 
  50 seconds – 65 oC 
  30 seconds – 72 oC 
4 cycles: 30 seconds – 96 oC 
  60 seconds – 55 oC 
  90 seconds – 72 oC 
300 seconds holding at 20oC. 
 
Three μl of loading buffer (Appendix, section 6.2) was then added to each well of the ASPCR 
reactions.  
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Agarose gel electrophoresis of samples 
Agarose gels were created using 5g agarose (Sigma, UK) and 500ml 0.5xTBE (Appendix, 
section 6.2) with 1 2  μl eth idium bromid e (Sigma, UK) added once the gel had cooled but 
before setting to aid visualization of the samples (see chapter 2, section 2.6). These were 
placed in a gel tank (Geneflow, UK) with a sufficient volume of 0.5xTBE to allow complete 
submersion of the gel. Twelve μl of ethidium bromide was also added to the surrounding TBE 
to further aid visualization of the samples. The initial volume of 12µl of ethidium bromide 
used in both the creation of the gels and in the surrounding TBE was later changed to 15µl as 
visualisation was poor when using the lower volume. The gel was electrophoresed for a total 
of 15 minutes using the following program: 
350 Volts 
300 amps 
150 Watts. 
The results were then visualised using an ultraviolet light box (Geneflow, UK) (see figure 3.4) 
 
DYNAL 
For some samples ambiguous results were obtained. This may have been due to several 
reasons including the degradation of the stored DNA sample, inefficient visualisation due to 
non-optimal volumes of reagents used or cross contamination. In order to resolve these, 
DYNAL AllSet+™ SSP kits (Invitrogen, UK) were employed to provide clarification of results 
via in depth analysis of specific HLA DRB1, DQA1 or DQB1 loci.   
 
For each  p atient and  control sample a solu tion of 4 8 0 μl of the DYNAL master mix, 5 7 μl 
Millq water, 57μl DNA sample and 4.8μl Taq (Bioline, UK) was produced and 10μl of this  
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Figure 3.4: Visualisation of agarose gel electrophoresis 
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solution added to each of the 48 wells on the PCR plate containing the ASPCR primers 
provided by DYNAL. The plate was then sealed with a plastic sealer (Griener, UK), and 
centrifuged at 1000rpm for 1 minute. The plates were then run on M J Research PTC-225 
Peltier Thermal cycler machine (Genetic Research Instrumentation, UK) using the following 
program: 
120 seconds denaturation – 96oC 
10 cycles: 15 seconds – 96 oC 
  60 seconds – 65 oC 
20 cycles: 10 seconds – 96 oC 
  50 seconds – 61 oC 
  30 seconds – 72 oC 
 
Three μl of loading buffer (Appendix, section 6.2) was then added to each well of the ASPCR 
reactions.  
 
All other conditions were as stated in the previous PCR section with the exception that 25µl 
ethidium bromide was added to the agarose gel during preparation in place of 15µl ethidium 
bromide.  
 
Any samples which remained ambiguous or failed completely were not included in the final 
results.  
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Analysis of case control data was performed using the Chi-squared (χ2) test with P < 0.05 
considered significant, with the Fisher’s exact test performed for samples with counts lower 
than 10.  Odds ratios (OR) and 95% confidence intervals (CI) were calculated using the 
method of Woolf with Haldane’s modification for small numbers (Woolf 1955). The Fisher’s 
exact test was performed using the MINITAB statistical package (MINITAB Release 14.1 © 
1972–2003, Minitab Inc, USA.); all other calculations were performed using Excel 
(Microsoft® Excel, © 1985-2003 Microsoft Corporation). (See Chapter 2, section 2.8) 
3.4.3 Statistical analysis 
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3.5 Results 
Genotyping results 
All cases and controls for each genotype were in Hardy Weinberg equilibrium. In total 625 
HT patients and 619 control subjects were successfully genotyped at the DRB1, DQB1 and 
DQA1 loci (Table 3.2). One allele from each of the DRB1, DQB1 and DQA1 regions was 
observed to have a strong association, DRB1*04 (P=0.002, OR=1.37, 95% CI 1.13-1.67), 
DQB1*0301/4 (P=3.47x10-4, OR=1.43, 95% CI=1.17-1.73) and DQA1*03011/12 
(P=1.53x10-4, OR=1.44, 95% CI=1.19-1.74). Small predisposing effects for HT were detected 
at DRB1*03, DRB1*08, DQB1*04, and DQA1*0401 (P=0.034-0.017, OR = 1.25-1.93). 
 
 Protective effects against the development of HT were also seen at DRB1*07, DRB1*13, 
DQB1*06, DQA1*01012/3 and DQA1*0201 (P=0.002, OR=0.72-0.79). No other 
associations were detected. 
 
Strong LD observed between the DRB1, DQB1, and DQA1 regions allowed analysis of 
classical HLA haplotypes to be performed (Table 3.3). A strong predisposing effect was seen 
for the DR4 haplotype (P=6.79x10-7 OR=1.98 [95% CI=1.51-2.59]). A strong association of 
each of the loci within this haplotype was also seen as mentioned previously; DRB1*04 
(P=0.002), DQB1*0301/4 (P=3.47x10-4) and DQA1*03011/12 (P=1.53x10-4). A weaker 
predisposing effect for DRB1*08-DQB1*04-DQA1*04 (DR8 haplotype) (P=0.038, OR=1.80, 
[95% CI=1.01-3.18]) was observed, all loci within this haplotype also demonstrated 
association. Protective effects were detected for  the DR7 haplotype  (P=0.013 OR=0.70 [95% 
CI=0.53-0.93]), DRB1*13-DQB1*06-DQA1*01 (DR13) (P=0.001 OR=0.61 [95% CI=0.45-
0.83]) and DRB1*15-DQB1*06-DQA1*01 (DR15) (P=0.034, OR=0.76 [95% CI=0.59-
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0.98]). All alleles within these haplotypes were shown to have association when investigated 
individually barring the DQB1*02 locus (P=0.703) within the DR7 haplotype. Although the 
DRB1*03 allele was seen to be associated with HT (P=0.034), only a borderline association 
of the DRB1*03-DQB1*02-DQA1*05 (DR3) haplotype with HT was detected (P=0.050) 
(Table 3.3). No other associations were detected (Table 3.4).  
   
Phenotype/genotype associations 
Data was only available to investigate associations between the presence or absence of diffuse 
goitre and serum TSH levels at time of diagnosis. Data on the presence or absence of diffuse 
goitre was only available for a total of 399 HT patients. Data for serum TSH levels was only 
available for 277 HT patients. No significant differences were seen between HLA class II 
alleles or haplotypes and individual phenotypes in presence or absence of diffuse goitre 
(Table 3.5) and HT sub-classified on the basis of TSH levels, 5.5-15 mIU/liter and > 15 
mIU/liter (Table 3.6).  
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Table 3.2: Distribution of DRB1, DQB1 and DQA1 alleles in patients with Hashimoto’s 
thyroiditis and control subjects 
 
P* - uncorrected P values 
Χ2 = Chi-squared, OR = Odds ratios, 95% CI = 95% confidence interval 
† - Number of HT patients = 625, number of control subjects = 619. Each sample produces 2 
haplotypes due to the diploid nature of the human genome 
  
HLA 
class II 
alleles 
Hashimoto’s 
thyroiditis 
n = 1250† 
( %) 
Control 
subjects 
 n = 1238† 
( %) Χ2 P* OR 95% CI 
  DRB1               
01 110 (8.80) 130 (10.50) 2.064 0.151      
03 247 (19.76) 204 (16.48) 4.514 0.034 1.25 1.02 - 1.53 
04 285 (22.80) 219 (17.69) 10.055 0.002 1.37 1.13 - 1.67 
07 152 (12.16) 185 (14.94) 4.115 0.043 0.79 0.63 – 0.99 
08 41 (3.28) 24 (1.94) 4.399 0.036 1.70 1.02 - 2.83 
09 24 (1.92) 21 (1.70) 0.175 0.675      
10 8 (0.64) 3 (0.24) FISHER 0.226      
11 77 (6.16) 81 (6.54) 0.153 0.695      
12 21 (1.68) 19 (1.53) 0.083 0.773      
13 104 (8.32) 132 (10.66) 3.975 0.046 0.76 0.58 - 1.00 
14 25 (2.00) 35 (2.83) 1.808 0.179      
15 148 (11.84) 177 (14.30) 3.307 0.069     
16 8 (0.64) 8 (0.65) 0.000 0.985     
 DQB1             
02 360 (28.80) 348 (28.11) 0.146 0.703      
0301/4 297 (23.76) 222 (17.93) 12.796 3.47x10-4 1.43 1.17 - 1.73 
0302 103 (8.24) 111 (8.97) 0.417 0.518      
03032 53 (4.24) 60 (4.85) 0.528 0.468      
0305 0 (0.00) 0 (0.00) - -     
04 37 (2.96) 20 (1.62) 5.023 0.025 1.84 1.06 - 3.18 
05 154 (12.32) 173 (13.97) 1.491 0.222      
06 246 (19.68) 304 (24.56) 8.587 0.003 0.75 0.62 - 0.91 
 DQA1             
0101/4 140 (11.20) 165 (13.33) 2.618 0.106      
0102/3 249 (19.92) 311 (25.12) 9.647 0.002 0.74 0.61 - 0.90 
0201 137 (10.96) 180 (14.54) 7.168 0.007 0.72 0.57 - 0.92 
03011/12 325 (26.00) 243 (19.63) 14.333 1.53 x10-4 1.44 1.19 - 1.74 
0302 1 (0.08) 0 (0.00) FISHER 1.000      
0401 37 (2.96) 19 (1.53) 5.743 0.017 1.93 1.11 - 3.38 
0501/2 361 (28.88) 317 (25.61) 3.363 0.067     
0601 0 (0.00) 3 (0.24) FISHER 0.123      
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Table 3.3: Distribution of associated DRB1, DQB1, DQA1 haplotypes in patients with 
Hashimoto’s thyroiditis and control subjects 
 
 
 
 
 
 
Table showing individuals displaying at least one copy of specified haplotype 
P* - uncorrected P values 
Χ2  = Chi-squared, OR = Odds ratios, 95% CI = 95% confidence interval 
 
  
HLA class II  
haplotypes (DRB1, 
DQB1, DQA1) Haplotype 
Hashimoto’s 
 Thyroiditis 
 n=625 (%) 
Control  
subjects 
 n=619 (%) Χ2 P* OR 95% CI 
03, 02, 0501/2 DR3 235 (37.60) 200 (32.31) 3.827 0.050 1.26 1.00 - 1.59 
04, 0301/4, 
03011/12 DR4 180 (28.80) 105 (16.96) 24.673 6.79 x 10-7 1.98 1.51 - 2.59 
07, 02, 0201 DR7 108 (17.28) 142 (22.94) 6.205 0.013 0.7 0.53 - 0.93 
08, 04, 0401 DR8 34 (5.44) 19 (3.07) 4.284 0.038 1.8 1.01 - 3.18 
13, 06, 01012/3 DR13 83 (13.28) 124 (20.03) 10.222 0.001 0.61 0.45 - 0.83 
15, 06, 0102/3 DR15 143 (22.88) 174 (28.11) 4.48 0.034 0.76 0.59 - 0.98 
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Table 3.4: Distribution of non-associated DRB1, DQB1, DQA1 haplotypes in patients 
with Hashimoto’s thyroiditis and control subjects 
 
 
 
 
 
 
Table showing individuals displaying at least one copy of specified haplotype 
P* - uncorrected P values 
Χ2 = Chi-squared, OR = Odds ratios, 95% CI = 95% confidence interval 
  
HLA class II haplotypes 
(DRB1, DQB1, DQA1) 
Hashimoto’s 
thyroiditis 
Control 
subjects 
Χ2 P* 
n = 625 
( %) 
n = 619 
( %) 
01, 0301/4, 0101/4 0 (0.00) 0 (0.00) - - 
01, 05, 0101/4 107 (17.12) 122 (19.71) 1.388 0.239 
03, 02, 0501/2 235 (37.60) 200 (32.31) 3.827 0.050 
03, 06, 0501/2 5 (0.80) 1 (0.16) FISHER 0.218 
04, 0302, 03011/12 93 (14.88) 110 (17.77) 1.903 0.168 
07, 02, 03011/12 12 (1.92) 4 (0.65) FISHER 0.075 
07, 03032, 0201 24 (3.84) 38 (6.14) 3.471 0.062 
07, 03032, 03011/12 2 (0.32) 0 (0.00) FISHER 0.500 
08, 0301/4, 0401 1 (0.16) 0 (0.00) FISHER 1.000 
09, 03032, 0301 20 (3.20) 21 (3.39) 0.036 0.849 
10, 05, 0101/4 6 (0.96) 3 (0.48) FISHER 0.506 
11, 0301/4, 0501/2 68 (10.88) 78 (12.60) 0.889 0.346 
11, 05, 0501/2 2 (0.32) 0 (0.00) FISHER 0.500 
11, 06, 0501/2 3 (0.48) 0 (0.00) FISHER 0.249 
12, 0301/4, 0501/2 1 (0.16) 0 (0.00) FISHER 1.000 
12, 05, 0501/2 0 (0.00) 0 (0.00) - - 
12, 06, 0501/2 1 (0.16) 0 (0.00) FISHER 1.000 
13, 02, 0201 0 (0.00) 0 (0.00) - - 
13, 02, 0301 0 (0.00) 0 (0.00) - - 
13, 0301/4, 0201 0 (0.00) 0 (0.00) - - 
13, 0301/4, 03011/12 0 (0.00) 0 (0.00) - - 
14, 0301/4, 03011/12 0 (3.52) 0 (0.00) - - 
14, 05, 001/4 22 (0.00) 35 (5.65) 3.240 0.072 
15, 0301/4, 0102/3 2 (0.32) 0 (0.00) FISHER 0.500 
16, 0301/4, 0101/4 0 (0.00) 0 (0.00) - - 
16, 05, 0101/4 3 (0.48) 5 (0.81) FISHER 0.504 
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Table 3.5: Distribution of DRB1, DQB1 and DQA1 alleles in patients with Hashimoto’s 
thyroiditis with a diffuse goitre and patients with Hashimotos thyroiditis with no goitre 
present 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P* - uncorrected P values 
FISHER = denotes that Fisher’s exact test was performed due to small sample numbers 
Χ2 = Chi-squared, OR = Odds ratios, 95% CI = 95% confidence interval 
† - Number of HT patients with goitre present = 221, number of HT patients with no goitre 
present = 178. Each sample produces 2 haplotypes due to the diploid nature of the human 
genome 
 
  
HLA 
class II 
alleles 
Diffuse goitre present 
n=442† (%) 
No goitre present  
n=356† (%) Χ2 P* OR 95%CI 
 DRB1          
0101/2/4 40 (9.03) 36 (9.86) 0.163 0.686     
1501-5 58 (13.09) 38 (10.41) 1.374 0.241     
1601-6 1 (0.23) 5 (1.37) FISHER 0.096     
0301-5 75 (16.93) 68 (18.63) 0.397 0.529     
0401-22 108 (24.38) 78 (21.37) 1.023 0.312     
0701 57 (12.87) 47 (12.88) 0.000 0.997     
0801-11 14 (3.16) 10 (2.74) 0.123 0.726     
0901 10 (2.26) 7 (1.92) 0.112 0.738     
1001 4 (0.90) 0 (0.00) FISHER 0.131     
1101-21 22 (4.97) 28 (7.67) 2.523 0.112     
1201-3 11 (2.48) 4 (1.10) 2.114 0.146     
1301-22 35 (7.90) 34 (9.32) 0.513 0.474     
1401-21 7 (1.58) 9 (2.47) 0.809 0.369         
 DQB1          
0305 0 (0.00) 0 (0.00) - -     
02 120 (27.09) 99 (27.12) 0.000 0.991     
04 11 (2.48) 10 (2.74) 0.052 0.819     
05 54 (12.19) 52 (14.25) 0.743 0.389     
0601-9 94 (21.22) 71 (19.45) 0.384 0.535     
0301/4 97 (21.90) 92 (25.21) 1.223 0.269     
0302 46 (10.38) 22 (6.03) 4.927 0.026 1.79 1.05 - 3.03 
03032 20 (4.51) 18 (4.93) 0.078 0.781         
 DQA1          
0101/4 49 (11.06) 46 (12.60) 0.459 0.498     
0102/3 94 (21.22) 72 (19.73) 0.273 0.601     
0201 51 (11.51) 42 (11.51) 0.000 0.998     
03011/12 124 (27.99) 91 (24.93) 0.959 0.327     
0302 1 (0.23) 0 (0.00) FISHER 1.000     
0401 12 (2.71) 9 (2.47) 0.047 0.829     
0501/2 111 (25.06) 104 (28.49) 1.210 0.271     
0601 0 (0.00) 0 (0.00) - -         
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Table 3.6: Distribution of DRB1, DQB1 and DQA1 alleles in patients with Hashimoto’s 
thyroiditis with TSH levels between 5.5-15mIU/liter and patients with Hashimotos 
thyroiditis with TSH levels greater than 15mIU/liter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P* - uncorrected P values 
FISHER = denotes that Fisher’s exact test was performed due to small sample numbers. Χ2  = 
Chi-squared, OR = Odds ratios, 95% CI = 95% confidence interval 
† - Number of HT patients where TSH=5.5 - 15mIU/liter = 128, number of HT patients where 
TSH >15mIU/liter = 149. Each sample produces 2 haplotypes due to the diploid nature of the 
human genome 
 
  
HLA class 
II alleles 
TSH = 5.5 - 15mIU/liter 
n=256† (%) 
TSH >15mIU/liter 
 n=298† (%) Χ2 P* 
 DRB1      
0101/2/4 20 (7.78) 35 (11.71) 2.387 0.122 
1501-5 31 (12.06) 29 (9.70) 0.802 0.371 
1601-6 0 (0.00) 2 (0.67) FISHER 0.502 
0301-5 42 (16.34) 66 (22.07) 2.900 0.089 
0401-22 65 (25.29) 63 (21.07) 1.390 0.238 
0701 33 (12.84) 39 (13.04) 0.005 0.943 
0801-11 7 (2.72) 5 (1.67) FISHER 0.560 
0901 7 (2.72) 5 (1.67) FISHER 0.560 
1001 1 (0.39) 0 (0.00) FISHER 0.462 
1101-21 13 (5.06) 21 (7.02) 0.930 0.335 
1201-3 5 (1.95) 5 (1.67) FISHER 1.000 
1301-22 26 (10.12) 24 (8.03) 0.738 0.390 
1401-21 6 (2.33) 4 (1.34) FISHER 0.525 
 DQB1      
0305 0 (0.00) 0 (0.00) - - 
02 66 (25.68) 96 (32.11) 2.764 0.096 
04 6 (2.33) 5 (1.67) FISHER 0.762 
05 31 (12.06) 42 (14.05) 0.477 0.490 
0601-9 51 (19.84) 54 (18.06) 0.287 0.592 
0301/4 65 (25.29) 70 (23.41) 0.266 0.606 
0302 22 (8.56) 20 (6.69) 0.693 0.405 
03032 15 (5.84) 11 (3.68) 1.443 0.230 
 DQA1      
0101/4 25 (9.73) 38 (12.71) 1.223 0.269 
0102/3 57 (22.18) 53 (17.73) 1.727 0.189 
0201 27 (10.51) 36 (12.04) 0.324 0.569 
03011/12 78 (30.35) 73 (24.41) 2.461 0.117 
0302 1 (0.39) 0 (0.00) FISHER 0.462 
0401 5 (1.95) 5 (1.67) FISHER 1.000 
0501/2 63 (24.51) 93 (31.10) 2.974 0.085 
0601 0 (0.00) 0 (0.00) - - 
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3.6 Discussion 
Although progress has been made in determining the genetic predisposition to GD, less is 
known about the genetic predisposition to HT, due in part to the use of small datasets and the 
assumption of genetic homology between both diseases. This study has investigated 
association of the HLA class II region, long known to be associated with several AIDs, in a 
large UK Caucasian HT case control dataset.   
 
The strongest association in this study was between the DR4 haplotype and HT. This was 
closely followed by the associations of the individual alleles included in this haplotype 
(DRB1*04, DQB1*0301/4 and DQA1*03011/12). As previously mentioned in section 3.2 
this is not the first time that association of the DR4 haplotypes and its included loci with HT 
has been proposed. The DR4 haplotype has been shown to be associated in two Caucasian 
cohorts (Petrone et al. 2001, Farid and Thompson 1986) and DRB1*04 has been associated in 
a Japanese HT cohort (Wan et al. 1995). Whilst the previous associations have been based on 
small cohort sizes this study does serve to support this association.  
 
Although there is limited data on previous associations with HT, the DR4 haplotype has long 
been associated with type 1 diabetes (T1D) (Cucca et al. 2001, Thomson et al. 1988). The 
shared epitope, a highly conserved amino acid sequence encoded in several DRB variations,  
including *0401, DRB1*0404, DRB1*0405 and DRB1*0408 has also been associated with 
rheumatoid arthritis (RA) (Gourraud et al. 2006). This may indicate that the DR4 haplotype is 
a common susceptibility haplotype for autoimmune disease, or more specifically for 
autoimmune disease centred around cellular destruction such as HT, T1D and RA. It was not 
possible to assess the impact of T1D and/or RA on the HLA class II associations found in this 
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study due to lack of available phenotype data concerning the autoimmune history of the 
patient or family history. This would however be useful to investigate as it may elucidate 
whether the association of DR4 was due to the coexistence of T1D and/or RA or if it is an 
independent association 
 
 
To understand this association and the possible general autoimmune connection, the function 
of the DR4 haplotype and included alleles must be investigated. Schonland et al demonstrated 
that individuals with the DRB1*04 allele exhibited shortening of the telomeres in both CD4+ 
T cells and granulocytes in the first two decades of life (Schonland et al. 2003). Telomeric 
shortening is known to lead to replicative senescence (Harley et al. 1990)however this is 
normally a gradual process which occurs over the course of a lifetime. The early onset 
telomeric shortening seen in the DRB1*04 positive individuals may lead to an accelerated 
replicative senescence of CD4+ T cells and granulocytes resulting in a decrease in cell 
turnover rates. This change in the nature of the T cell population may reduce the efficacy of 
the immune system in response to antigenic stimuli. It may be that the T cells entering 
senescence are unable to prevent autoreactive cells from expanding. Alternatively it may be 
that the senescent T cells, which are less responsive to controlling stimuli, attack the hosts 
own cells (Sakaguchi 2000, Schonland et al. 2003).  
 
The DRB1*03 allele and DR3 haplotype have however been previously associated with GD 
(Simmonds et al. 2005). In particular the strong DR3 association with GD seen in a study by 
Heward et al. and then expanded upon in a study by Simmonds et al. can be compared to the 
results in this thesis with some accuracy (Simmonds et al. 2005, Heward et al. 1998). The HT 
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patients recruited for this study are UK Caucasians and are part of the UK national AITD 
collection (Manji et al. 2006). They are taken from the same sample population as that used to 
recruit GD patients in both Heward’s and Simmonds’ GD studies and the same control set has 
been used for all three studies hence allowing comparative analysis. The strong association of 
DR4 and weak association of DR3 in this HT study are in marked contrast to Heward’s GD 
study where DR3 was the strongest association noted (Heward et al. 1998). This study was 
furthered by Simmonds et al. and again showed an increase in the DR3 haplotype and further 
confirmed the association of the DRB1*03 allele with GD by showing not only an association 
of a single copy of DRB1*03 (OR 1.94; 95% CI 1.52–2.48) but that individuals homozygous 
for DRB1*03 showed even stronger association (OR 3.49; 95% CI 1.77–6.87) (Simmonds et 
al. 2005). This provides a strong case for the theory that the genetic causal factors of GD and 
HT are, at least in part, different.  
 
 
Although both HT and GD are centred around autoimmune attack of the thyroid gland there 
are many differences in the etiology and pathogenesis of the two diseases (see chapter 1, 
sections 1.4.2 and 1.4.3). This may imply that the relationship of genetic causal factors 
between HT and GD are similar to that between HT and other autoimmune diseases. Whilst 
some causal factors will be common to both, some will show association only with one. One 
of the striking differences between HT and GD is the involvement of TSHR autoantibodies. 
Whilst in GD the formation of TSHR autoantibodies results in increased thyroid hormone 
production and is a key factor in the pathogenesis of the disease, TSHR autoantibodies are not 
seen in HT (see Chapter 1, section 1.4). Association of the TSHR gene with GD has also been 
reported in GD (Brand et al. 2009)  but not in HT (see chapter 1 section 1.8). It may be 
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therefore that the DR3 haplotype is involved in the production of TSHR autoantibodies, a 
feature unique to GD, hence the lack of association seen in this HT study. Similarly the DR4 
haplotype, seen to be associated with HT but not GD may be involved in the as yet poorly 
understood mechanism of action for thyrocyte destruction in HT.  
 
In this study protective roles were detected for DRB1*07 and the DR7 haplotype and a trend 
towards a predisposing role for the DRB1*08 allele and DR8 haplotype. In contrast to the 
differences observed with the predisposing associations, the DR7 and DR8 haplotypes have 
also been identified as having a protective role in GD (Simmonds et al. 2005).  Whilst there 
are many differences between the pathogenesis of these two AITDs there are also some 
common aspects such as the presence of Tg and TPO autoantibodies. It may be that the DR7 
and/or DR8 haplotypes protect against one or both of these autoantibody colonies forming.  
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CHAPTER 4: MICA AND MICB 
4.1 Introduction 
The HLA class I region spans approximately 1.8Mb on chromosome 6. There are potentially 
118 genes in this region however only 34 have been shown to be expressed, the remainder 
being pseudogenes, sequence tagged sites, potential coding sequences or expressed sequences 
(Shiina et al. 1999). The HLA Class I loci are subdivided into the classical and non-classical 
genes. The classical genes are further grouped into HLA-A, HLA-B and HLA-C whilst the 
non-classical genes comprise of the HLA-D, HLA-E, HLA-F and HLA-G groups, the MIC 
genes and a variety of other genes. (Bahram et al. 1994, Klein and O'HUigin 1994).  
4.1.1 HLA Class I 
 
Structure and function of the HLA Class I molecules 
The HLA Class I genes are all remarkably similar in basic structure. All HLA Class I genes 
begin with a 5’ leader exon which encodes a short signal peptide. This region is followed by 3 
exons which encode the extracellular α1, α2, α3 domains of the HLA Class I molecule. The 
exon encoding the transmembrane region of the molecule follows this and finally a 3’ 
terminal exon encoding the cytoplasmic domains. All HLA Class I genes follow this pattern 
with the only apparent differences being whether the α chain is encoded by 5 or 6 exons and 
whether there are 1 or 2 terminal exons (Goldsby and Goldsby 2003).  
 
The HLA Class I molecule is comp rised  of a 45  kilod alton (k Da) α chain  non-covalently 
associated with a 12 kDa β2-microglobulin molecule (Goldsby and Goldsby 2003).  Whilst the 
α chain  is encod ed  b y the HLA Class I g enes on chromosome 6 , the β2-microglobulin 
molecule is encoded by a highly conserved gene located at 15q21-q22. The hydrophobic 
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transmembrane region and hydrophilic cytoplasmic tail of the α chain anchors the α chain and 
β2-microglobulin dimer in the plasma membrane (see Figure 3.3) 
 
The primary function of the HLA class I genes is to encode glycoproteins involved in the 
presentation of endogenous peptide antigens to cytotoxic T cells (Tc cells) (see chapter 1, 
section 1.2).  
 
HLA Class I molecules bind peptides derived from endogenous intracellular proteins. Proteins 
present within the cell such as those from expressed viral genes, become associated with 
molecules of ubiquitin. The ubiquitin-protein complex is then degraded by a multifunctional 
protease complex called a proteasome, including specialised proteases proteasome subunit 
beta-type 9 (PSMB9), proteasome subunit beta-type 8 (PSMB8) and proteasome subunit beta-
type 10 (PSMB10), within the central hollow of the proteasome into short length peptides for 
association with HLA class I molecules. This process is part of the cytosolic processing 
pathway present in all cells that allows the proteins, once digested in the cytosol, to be 
transported to the cisternae of the endoplasmic reticulum which is aided by the transporter 
associated with antigen processing (TAP) heterodimer. The TAP heterodimer is comprised of 
TAP1 and TAP2 protein subunits (Goldsby and Goldsby 2003). Each of the subunits is 
similar in configuration and has a domain projecting into the lumen of the rough endoplasmic 
reticulum (RER) and a domain that projects into the cytosol. The domain projecting into the 
cytosol also binds adenosine triphosphates (ATP), which facilitates TAPs function in the 
ATP-dependent transport of amino acids, sugars, ions and peptides. Although TAP mediates 
several transport of several molecules it shows the highest affinity for peptides of 8-10 amino 
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acids and peptides with hydrophobic or basic C-terminal amino acids, which are also the 
optimal length and peptide anchor residues for binding by HLA class I molecules.  
 
 The mature HLA class I molecule consists of an alpha chain and a β2-microglobulin chain 
which are synthesised as separate units on polysomes present on the (RER) of the cell. A 
chaperone molecule, calnexin associates with the α chain aiding in the folding of the protein 
chain. The β2-microglobulin chain then binds to the α chain causing the calnexin molecule to 
be released and a new chaperone molecule, calreticulin, to associate with the now joined α 
and β2-microglobulin chains. For the HLA class I molecule to become a stable unit which can 
then exit the RER a peptide must be present in the binding site of the molecule. The TAP 
assisted protein (tapasin) associates with the HLA class I around the same time as the 
association of calrecticulin occurs. Tapasin brings the TAP complex and HLA class I 
molecule together allowing transport of the peptides through the membrane of the RER. This 
HLA class I tapasin complex allows capture of the peptide formed from the proteasome 
before it can be degraded by the RER lumen. The now stable HLA class I complex can leave 
the RER and move towards the cell surface. Each HLA Class I molecule binds unique sets of 
peptides and on average a single cell can express around 105 copies of each class I molecule, 
enabling a great variety of different peptides to be expressed simultaneously (Goldsby and 
Goldsby 2003).  
 
Although the classical HLA class I genes are the most commonly investigated the non-
classical HLA class I genes, are also worthy of investigation. The six MHC class I chain-
related (MIC) genes, MICA, MICB, MICC, MICD, MICE and MICF are all non-classical 
4.2 MICA and MICB 
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class I HLA genes. Only two of these genes, MICA and MICB are expressed and produce 
protein products (Janeway 2005, Frigoul and Lefranc 2005). Unlike the majority of the HLA 
region MICA and MICB were only identified relatively recently in 1994 (Bahram et al. 1994) 
and as a result there still much to be learned about their structure and function. 
 
MICA and MICB gene structure  
MICA is located at 6p21.3, 46.4kb centromeric to HLA-B and MICB 70kb centromeric to 
MICA. The initial study in 1994 concluded that MICA consisted of a single long open reading 
frame of 1149bp and encodes a 383 amino acid long polypeptide with a relative molecular 
mass of 43kDa (Bahram et al. 1994). Since then it has become apparent that a microsatellite 
polymorphism in exon 5 consisting of between four to ten GCT repeats encoding four to ten 
alanine amino acids means that MICA is between 360 and 366 amino acids in length (Frigoul 
and Lefranc 2005).  
 
The structure of the MICA gene and protein is similar to that of classical HLA class I genes 
and encoded proteins. There are three external domains, α1, α2, α3, two distal G-like 
domains, a C-like domain, connecting region, transmembrane region and a cytoplasmic tail. 
The protein is highly glycosylated with 3 glycosylation sites in the G like domains and 5 in 
the C-like domain. In marked difference to the classical HLA class I molecules the expression 
of the MICA protein does not require, nor has found to be associated with either peptide or β2 
microglobulin (Rodriguez-Rodero et al. 2007). Whilst similar to that of classical HLA class I 
genes, the structure of the MICA gene has some variations. Exon 1, which is 70bp in length 
and encodes the L-region. Similarly to classical HLA class I molecules this first exon encodes 
a signal peptide. Exon 2 is 255bp and encodes the first extracellular distal G-like domain of 
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85 amino acids. This is in contrast to the single exon of classical HLA class I molecules. Exon 
3 is 288bp and encodes the second of the distal G-like domains, 96 amino acids in length. 
Exon 4 is 279bp in length and encodes the 279 amino acid C-like domain. Exon 5 contains the 
microsatellite polymorphism hence can be between 132 and 150bp. Exon 5 encodes the 12 
amino acid connecting region, the transmembrane region which can be between 19 and 25 
amino acids in length owing to the polymorphism and finally 13 amino acids of the 
cytoplasmic region. A very large intron of 2551bp separates exon 5 from exon 6 which is 
itself 125bp in length and codes the remaining 42 amino acids of the cytoplasmic region and 
3’ untranslated region. This is in contrast to the separation of the exon encoding the 
cytoplasmic tail and untranslated regions in classical HLA class I genes.  
 
Whilst there are similarities in the overall genetic and protein structure of MICA and MICB to 
classical HLA class I genes and molecules there is little similarity in the genetic sequences 
with the MIC genes showing only 15-30% sequence identity (Goldsby and Goldsby 2003).  
MICA and MICB are extremely similar sharing 91% identity in their coding sequences 
(Bahram et al. 1994).  Although this primary knowledge is known about MICA, there has 
been little work on the structure and function of MICB and the associated protein products. 
 
Function of MICA and MICB genes 
It was initially presumed that the expression of MICA and MICB was restricted mainly to 
intestinal epithelial cells (Groh et al. 1996). However a more recent study has shown that 
MICA and MICB were transcribed in every tissue type examined with the exception of the 
central nervous system indicating that it has the potential to be transcribed in nearly all tissue 
types (Schrambach et al. 2007). MICA and MICB are expressed in response to cellular stress 
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or injury, in particular in response to heat shock protein formation due to either heat or 
oxidative stress from hydrogen peroxide (Frigoul and Lefranc 2005). The MICA and MICB 
protein chains are expressed on the surface of these cells where they can be recognised by a 
receptor on natural killer (NK) cells, and a specific subset of T cells, γδT cells and CD8+ αβT 
cells (Bauer et al. 1999). Of particular interest is the γδT cell subset which carry the activating 
C-type lectin NK receptor killer cell lectin-like receptor, subfamily K, member 1 (KLRK1) 
which MICA and MICB molecules bind to, with a single MIC molecule binding to each 
KLRK1 homodimer. This then induces apoptosis of the affected cell. 
 
There has not been a great deal of previous work performed concerning MICA association 
with autoimmune disease (AID) and even less concerning MICB however a few associations 
have previously been reported. Five alleles of exon 5 (see MICA and MICB gene structure), 
each consisting of GCT trinucleotide repetitions have been identified. These are denoted as 
MICA4, MICA5, MICA6, MICA9 and MICA5.1, each referring to the number of 
trinucleotide repeats present in that allele. MICA5.1 is so named due to the repetition 
consisting of 5 GGCT rather than the trinucleotide GCT (Gambelunghe et al. 2000).  
4.2.1 Previous associations of MICA and MICB with AID 
 
Only one previous study has shown evidence of association of MICA with HT. In a German 
cohort of 129 GD patients, 56 HT patients and 206 controls weak association of MICA9 was 
observed (P=0.016). In addition weak association of the MICA5.1/MICA9 haplotype was 
seen (P=0.025, OR=2.5, 95%CI=1.2-5.4) (Ide et al. 2007). This study was performed in a 
mixed dataset using a very small HT cohort; the results therefore should be treated with 
caution until replicated in a larger dataset. 
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In a study performed by Gambelunghe et al. on a cohort of 195 type 1 diabetes (TID) patients 
and 158 controls association of the MICA5 allele was observed (OR=5.1; corrected P(Pc) < 
0.0005) MICA5.1  was also seen to be associated with adult onset T1D in this study (OR= 
7.0; corrected P (Pc) < 0.001) (Gambelunghe et al. 2001). The MICA5 and MICA5.1 alleles 
were not however found to be associated in a Korean cohort whereas a borderline association 
of MICA6 was reported. In addition to this the same Korean study also found evidence for 
MICA4 as a protective factor against T1D (Relative risk (RR)=0.44, Pc<0.01) (Park et al. 
2001). Whilst it should be noted the associations found in both studies were weak the lack of 
replication does not necessarily point to a false positive in either study. It may be that the 
different genetic backgrounds of the different ethnic groups used in the two studies 
contributed to this discrepancy. This phenomenon has been seen previously in the TSHR gene 
in GD when association within UK Caucasians was located to intron 1 and in Japanese GD 
patients was located in intron 7 (Dechairo et al. 2005, Hiratani et al. 2005). Additional 
associations of MICA5.1 and MICA-129met have also been observed in Addison’s disease 
(OR=22, Pc<10 −3) (Park et al. 2002) and ankylosing spondylitis (Pc=0.006, OR=2.57; 
95%CI=1.29–5.1) (Amroun et al. 2005) respectively. 
 
In a study performed by Lo et al. on a cohort of 129 GD patients and 396 controls several 
associations were observed (Lo et al. 2003). The MICA5/MICA5 haplotype was associated 
(RR=2.49, 95% CI=1.52–4.10, 0.00024, Pc=0.0035) as was the MICA5/MICA5.1 haplotype 
(RR=2.13, 95% CI=1.31–3.47, P=0.0020, Pc=0.030). In addition the MICA5 allele was 
strongly associated (RR=2.12; 95%CI=1.59–2.82; P=1.9 x 10-7; Pc=9.5 x 10-7). The 
MICA5.1/MICA5.1 haplotype was seen to be protective (RR=0.09, 95% CI=0.01–0.66, 
P=0.0030, Pc=0.044) (Lo et al. 2003). It can be seen that as MICA5.1/MICA5.1 was 
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protective but MICA5/MICA5.1 was not, two copies of the MICA5.1 alleles are required to 
confer protection. An unusual factor about this study is that was performed on children with 
GD and as GD does not commonly present until the fourth decade of life the results may be 
specific to early onset GD.  
 
It should also be noted that of all the associations mentioned, with the exception of the A5 
allele in the study by Lo et al., all were relatively weak associations. Due to lack of consistent 
replication of these studies it is difficult to say whether this is due to the MICA gene having 
only a low impact on pathogenesis of AID or whether some of these may be false positives 
due to underpowered studies (see Chapter 2, section 2.8.1)   
 
Although little work has been done concerning the MICB gene some associations have been 
recorded. The MICB0106 allele was found to be strongly associated with coeliac disease (Pc< 
0.000001, OR=5.6, 95%CI=3.1–10.1) (Gonzalez et al. 2004) and the MICB004 allele with 
rheumatoid arthritis  (Pc=0.01, OR=2.2, 95%CI=1.3–3.7) (Lopez-Arbesu et al. 2007). Both 
studies did however suggest that the association of these MICB alleles may be due to the 
strong LD of the area causing other HLA associations to be interpreted as a MICB, 
independent association.  
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Due to the important role of the HLA region in encoding key immune response genes it is 
possible that additional susceptibility loci may be present within this gene dense region above 
and beyond the known HLA class II association I have detected previously (refer to Chapter 
3). The role of MICA and MICB in the causation of apoptosis could indicate that these genes 
play a role in the thyrocyte destruction seen in HT. Although the results for MICA and MICB 
in autoimmune disease have varied, only a very limited amount of work has been performed 
in AITD 
4.3 Aims 
i. To genotype a large cohort comprising of HT patients and controls using TagSNPs 
to cover the majority of common polymorphisms with a minor allele frequency of 
> 20% within MICA and MICB. 
ii. To determine the predisposing and protective factors within the MICA and MICB 
genes via statistical analysis of TagSNP frequencies.  
 
 
4.4 Methods 
The sample cohort comprised of 745 individuals with HT and 617 control subjects 
(comprising of 288 control subjects from the Birmingham control collection and 329 control 
subjects taken from the 1958 birth cohort control set) as described in Chapter 2, section 2.1. 
4.4.1 Subjects 
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Genotyping data for the MICA and MICB regions was obtained from the International 
Haplotype mapping project web site [www.hapmap.org] (using the July ’06 release and a 
minor allele frequency (MAF) of 0.2) and then processed using the Haploview program 
(version 3.32) [www.hapmap.org/haploview_help.html]. Power calculations determined that 
with this smple cohort and a MAF of 0.2 there was power to exclude an effect of OR=1.3 or 
above (see Chapter 2, section 2.8.1). For MICA a region of 11.7Kb was identified containing 
10 TagSNPs covering a total of 14 variants. For MICB a region of 12.9Kb was identified 
containing 5 TagSNPs covering an additional 14 variants. For both gene regions all SNPs 
with an r2>0.80 were tagged.  
4.4.2 Genotyping 
 
Pre-designed genotyping assays for rs1131896, rs1131904, rs2256175, rs2844519, 
rs2855812, rs2853977, rs3130615, and rs9267390 were purchased from Applied Biosystems, 
UK. No previous assays had been designed for rs2523497, rs2844514, rs2844518, rs2853975, 
rs3131638, rs6934187 and rs7383312 so the sequences surrounding these SNPs (see 
Appendix, section 6.5) were submitted to Applied Biosystems, UK and genotyping assays 
designed and validated. All assays were genotyped on an ABI7900 HT using TaqMan® 
genotyping technologies (Applied Biosystems, UK).   
 
The DNA was prepared as previously described in Chapter 2 sections 2.2 and 2,3.  
4.4.3 Method 
DNA samples were previously diluted to a concentration of 20ng/ul and stored in 96 well 
plates. 2.25 µl of each 20ng/ul DNA sample was aliquoted from four different 96 well plates 
of samples into separate wells on a 384 well plate (Applied Biosystems, UK). On each plate 
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2.25 µl of Millq water was used in place of DNA in a minimum of four wells to be used as 
non-template controls (NTC) to check for plate contamination.  
 
A reaction solution comprising of 2.75 µl Applied Biosystems genotyping master mix 
(Applied Biosystems, UK), 0.18 µl of genotyping assay (Applied Biosystems, UK) and 0.09 
µl millq water was aliquoted into each well of the 384 well plate including the NTCs. The 
plate was then sealed with an optically clear sealer (Griener, UK), and centrifuged at 1000rpm 
for 1 minute. The plates were then run on M J Research PTC-225 Peltier Thermal cycler 
machine (Genetic Research Instrumentation, UK) using the following PCR program: 
 
120 seconds Taq activation - 50oC 
600 seconds denaturation - 95oC  
40 cycles:  15 seconds denaturation - 92oC  
  60 seconds annealing and extension - 60oC        
 
Conventionally in PCR reactions the annealing and extension stages are separate with the 
annealing stage being at a lower temperature than that of the extension. However in this 
process the primers have been designed by Applied Biosystems to anneal at a higher 
temperature, thus a separate stage is not required (http://www.appliedbiosystems.com). This 
reduces the time required for the PCR process and also reduces risk of contamination by 
allowing the temperature to remain high during this stage. 
 
All assays contained two probes; VIC and FAM to detect alleles 1 and 2 respectively (see 
Figure 2.4 for binding process) of the SNP being assayed. Each assay is provided with 
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information concerning which allele of a given SNP represents allele 1 and which allele 
presents allele 2. The probe will bind to the DNA present in accordance with the allele 
exhibited; in a heterozygous sample VIC and FAM will both bind in a homozygous sample 
only one type of probe will bind. The probes fluoresce with different wavelengths enabling 
the sample to be read using the ABI7900 prism (Applied Biosystems, UK).  
 
The results from the ABI7900 prism were incorporated into the SDS software (Version 2.2.2, 
Applied Biosystems, UK). The preliminary results were displayed in both a graphical and 
tabular form (see Figure 4.1). From this the initial validity of the results could be assessed. 
Using the graphical representation any results which did not appear to fall into one of the two 
homozygote or the heterozygote groupings (and which were not previously defined as NTCs) 
could be considered as outliers and repeated or eliminated from further analysis. Any of the 
samples defined as NTCs which did not fall into the NTC grouping demonstrated a possible 
contamination of the plate by extraneous DNA and would necessitate the repetition of the 
entire plate. If the results did not appear to group at all or an abnormal grouping was observed 
then the validity of the results was checked via the tablature representation. By comparing the 
strength of fluorescence for each of the two probes in each individual well it could be 
determined whether the grouping was an anomaly due to the failure of the assay or the DNA. 
4.4.4 Analysis 
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Figure 4.1: Schematic of allelic results 
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4.4.5 Statistical analysis 
Analysis of case control data was performed using the Chi-squared (χ2) test with P < 0.05 
considered significant, with the Fisher’s exact test performed for samples with counts lower 
than 10.  Odds ratios (OR) and 95% confidence intervals (CI) were calculated using the 
method of Woolf with Haldane’s modification for small numbers (Woolf 1955). The Fisher’s 
exact test was performed using the MINITAB statistical package (MINITAB Release 14.1 © 
1972–2003, Minitab Inc, USA.); all other calculations were performed using Excel 
(Microsoft® Excel, © 1985-2003 Microsoft Corporation).  
 
4.5 Results 
Genotyping results 
All cases and controls for each assay were in Hardy Weinberg equilibrium. No differences 
were observed between HT cases and controls for either genotype or allele frequencies for 13 
of the SNPs assayed (rs1131904, rs2256175, rs2523497, rs2844514, rs2844518, rs2844519, 
rs2853977, rs2855812, rs3130615, rs3131638, rs6934187, rs7383312 and rs9267390). A 
small association (P=0.024) was observed for the TT genotype of MICA SNP rs2853975 
SNP with a similar association (P=0.030, OR=1.21, 95% CI= 1.02-1.43) for the T allele. (see 
Tables 4.1 and 4.2).  
 
Although the assay for the rs1131896 SNP was purchased and initial genotype investigations 
carried out, information from this assay was unavailable for the final data analysis. Despite 
several replications no fluorescence was seen in samples processed with this assay indicating 
that the probe had not bound to the target DNA. As results were gained from all other assays 
it can be concluded that the DNA was of sufficient quality and rather the design of the 
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sequence used in the rs1131896 SNP assay was at fault. As no other SNPs were present in this 
TagSNP group there was no viable alternative. Had more time been available for this project a 
redesigned sequence could have been submitted to attempt to reassess the association of this 
SNP.  
 
Phenotype/genotype associations  
Insufficient data was available for phenotype correlations. Only partial data had been 
collected or was available on the various phenotypes of the HT patients used in this study. 
The numbers of patients with available data for each phenotype was so small as to greatly 
underpower the analysis. 
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Table 4.1: Distribution of alleles and genotypes in MICA SNPs in patients with 
Hashimoto’s thyroiditis and control subjects 
  
SNP 
Allele/ 
Genotype 
Hashimoto’s thyroiditis  
n = 754 ( %) 
Control subjects  
n = 633 ( %) Χ2 P OR 95% CI 
rs1131904 AA 418 (62.48) 312 (62.28) 0.214 0.643   
 AG 224 (17.09) 166 (33.13)     
 GG 27 (1.98) 23 (4.59)     
 A 1060 (79.22) 790 (78.84) 0.050 0.823 0.98 0.80-1.19 
 G 278 (20.78) 212 (21.16)     
          
rs2256175 GG 235 (36.27) 168 (32.56) 3.438 0.064   
 GA 303 (46.76) 273 (52.91)     
 AA 110 (16.98) 75 (14.53)     
 G 773 (59.65) 609 (59.01) 0.096 0.757 0.97 0.83-1.15 
 A 523 (40.35) 423 (40.99)     
          
rs2523497 AA 309 (45.64) 247 (46.78) 0.586 0.444   
 AG 295 (23.03) 231 (43.75)     
 GG 73 (5.12) 50 (9.47)     
 A 913 (67.43) 725 (68.66) 0.409 0.522 1.06 0.89-1.26 
 G 441 (32.57) 331 (31.34)     
          
rs2844514 AA 106 (15.21) 78 (15.23) 3.211 0.073   
 AG 346 (49.64) 227 (44.34)     
 GG 245 (35.15) 207 (40.43)     
 A 558 (40.03) 383 (37.40) 1.713 0.191 1.12 0.95-1.32 
 G 836 (59.97) 641 (62.60)     
          
rs2844518 AA 81 (13.04) 82 (15.05) 1.017 0.313   
 AG 290 (29.23) 242 (44.40)     
 GG 250 (16.76) 221 (40.55)     
 A 452 (36.39) 406 (37.25) 0.182 0.669 0.96 0.81-1.14 
 G 790 (63.61) 684 (62.75)     
          
rs2844519 GG 453 (65.18) 364 (62.65) 1.052 0.305   
 GA 219 (31.51) 193 (33.22)     
 AA 23 (3.31) 24 (4.13)     
 G 1125 (80.94) 921 (79.26) 1.118 0.290 0.90 0.74-1.09 
 A 265 (19.06) 241 (20.74)     
          
rs2853975 TT 76 (11.24) 46 (7.93) 5.078 0.024   
 TA 294 (43.49) 244 (42.07)     
 AA 306 (45.27) 290 (50.00)     
 T 446 (32.99) 336 (28.97) 4.712 0.030 1.21 1.02-1.43 
 AA 906 (67.01) 824 (71.03)     
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Allelic variations on the forward strand are shown.  
Χ2  = Chi-squared, OR = Odds ratios, 95% CI = 95% confidence interval 
  
SNP 
Allele/ 
Genotype 
Hashimoto’s thyroiditis 
n = 754 ( %) 
Control subjects  
n = 633 ( %) Χ2 P OR 95% CI 
rs2853977 TT 190 (27.90) 127 (24.19) 2.329 0.127   
 TA 336 (49.34) 283 (53.90)     
 AA 155 (22.76) 115 (21.90)     
 T 716 (52.57) 537 (51.14) 0.484 0.487 0.94 0.80-1.11 
 A 646 (47.43) 513 (48.86)     
          
rs6934187 GG 340 (54.31) 314 (55.28) 2.959 0.085   
 GC 236 (19.63) 223 (39.26)     
 CC 50 (3.84) 31 (5.46)     
 G 916 (73.16) 851 (74.91) 0.947 0.331 1.10 0.91-1.32 
 C 336 (26.84) 285 (25.09)     
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Table 4.2: Distribution of alleles and genotypes in MICB SNPs in patients with 
Hashimoto’s thyroiditis and control subjects 
 
 
 
 
Allelic variations on the forward strand are shown. 
Χ2  = Chi-squared, OR = Odds ratios, 95% CI = 95% confidence interval 
  
SNP 
Allele/ 
Genotype 
Hashimoto’s thyroiditis 
 n = 754 ( %) 
Control subjects   
n = 633 ( %)  Χ2 P OR 95% CI 
rs2855812 GG 339 (49.78) 308 (54.13) 1.909 0.167   
 GT 294 (43.17) 225 (39.54)     
 TT 48 (7.05) 36 (6.33)     
 G 972 (71.37) 841 (73.90) 2.001 0.157 1.14 0.95-1.36 
 T 390 (28.63) 297 (26.10)     
          
rs3130615 TT 391 (57.33) 303 (56.95) 0.094 0.760   
 TC 254 (19.14) 198 (37.22)     
 CC 37 (2.64) 31 (5.83)     
 T 1036 (75.95) 804 (75.56) 0.049 0.824 0.98 0.81-1.18 
 C 328 (24.05) 260 (24.44)     
          
rs3131638 CC 33 (4.90) 27 (4.66) 0.077 0.781   
 CT 230 (24.57) 195 (33.68)     
 TT 410 (23.35) 357 (61.66)     
 C 296 (21.99) 249 (21.50) 0.087 0.768 1.03 0.85-1.24 
 T 1050 (78.01) 909 (78.50)     
          
rs7383312 AA 75 (10.93) 80 (13.89) 2.888 0.089   
 AG 318 (29.47) 267 (46.35)     
 GG 293 (17.60) 229 (39.76)     
 A 468 (34.11) 427 (37.07) 2.390 0.122 0.88 0.75-1.04 
 G 904 (65.89) 725 (62.93)     
          
rs9267390 AA 293 (45.08) 245 (46.85) 0.301 0.583   
 AG 288 (23.40) 224 (42.83)     
 GG 69 (5.04) 54 (10.33)     
 A 874 (67.23) 714 (68.26) 0.281 0.596 1.05 0.88-1.25 
  G 426 (32.77) 332 (31.74)      
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4.6 Discussion 
For association of MICA with HT 10 TagSNPs covering a total of 14 variants were 
investigated and for association of MICB 5 TagSNPs covering an additional 14 variants were 
investigated. Of the 15 investigated SNPs one was not able to provide genotype data (see 
section 4.5). Of the remaining 14 SNPs investigated weak association with HT was seen in 
one, rs2853975. Only one previous HT study has been performed investigating association of 
MICA where a small positive correlation was observed for the A9 allele (P=0.016) and 
A5.1/A9 genotype ( P=0.025, OR=2.5, 95%CI=1.2-5.4) (Ide et al. 2007). This is a similar 
level of effect to the small positive correlation observed in this study for the TT genotype 
(P=0.024) and T allele (P=0.030, OR=1.21, 95% CI= 1.02-1.43) of rs2853975. Whilst this 
study has added further evidence for the role of MICA in HT by performing this investigation 
in a larger cohort, 745 HT patients were analysed in comparison to 56 in the study performed 
by Ide et al.(Ide et al. 2007), both results were weak positives. Had a smaller P value been 
observed in this study then it would seek to confirm the association of MICA with HT, 
however as neither study showed association stronger than P=0.024 there may be other 
factors to consider. Although it is considered a ‘significant’ association, being below the 
boundary of P=0.05 it is only just so, the weak association may be due instead to a 
coincidentally high proportion of MICA polymorphisms in the affected individuals rather 
than to the associated polymorphisms being causal factors for disease pathogenesis.  
 
The strong LD within this region should also be taken into account when viewing both the 
results from this study and that by Ide et al. As stated previously one of the main problems 
with determining a reliable result in the HLA region and extended region is the issue of strong 
LD. The findings of this study may not reflect an independent association but rather an 
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association of a nearby region within strong LD. To determine the likelihood of LD playing a 
role in the association observed in this study further analysis would need to be performed 
however due to the time constraints of this investigation it was not possible to do so for this 
thesis. The primary goal would be to attempt to identify the common LD blocks within the 
region surrounding and including MICA. This could be performed via use of data available at 
the International haplotype mapping project web site [www.hapmap.org] and further 
processed using the Haploview program [www.hapmap.org/haploview_help.html]. Loci 
which then proved to be in strong LD with MICA polymorphisms, in particular with the 
associated SNP rs2853975, could be genotyped in the same cohort as used for the initial 
study.  
 
Although LD only usually extends up to 200kb, LD within the HLA region can extend much 
further including LD seen between the HLA class II and class I regions (Pritchard and 
Przeworski 2001, Chapman et al. 2003, Gabriel et al. 2002). Several associations within the 
HLA class II gene region with HT have been detected (see Chapter 3), including very strong 
association of the DR4 haplotype and individual included alleles (See chapter 3). LD analysis 
between MICA/MICB and components of the DR4 haplotype would therefore be of benefit to 
determine if this weak association detected in rs2853975 could be due to weak LD with DR4. 
 
The HLA gene region in general is of great interest concerning autoimmune disease due to the 
involvement of numerous HLA class I, class II and class III genes with the immune response 
(see chapter 1, chapter 3 and section 4.1 for further details). As HT is a multifactorial 
autoimmune disease it may be that there are several causal factors within the entire HLA gene 
region contributing to HT. However, it may be that there are a small number of highly 
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associated casual factors within this region that are in areas of strong LD. If this is the case 
then it is not unlikely that any number of falsely associated loci would be detected in studies 
investigating the association of the HLA gene region with HT.  
 
Due to time constraints further screening was not possible. Ideally to further this work work 
the remainder of the genetic variation within MICA and MICB and the surrounding areas 
would be investigated. SNPs with at least a MAF of 0.20 were chosen for this study. For 
MICA 10 TagSNPs capturing a total of 14 variations were genotyped, decreasing the MAF to 
0.10 would allow 13 TagSNPs to cover a total of 24 variations. For MICB 5 TagSNPs 
covering 14 variants were identified and genotyped, decreasing the MAF to 0.10 would allow 
8 TagSNPS to cover a total of 27 variations ([www.hapmap.org] using the July ’06 release). 
By increasing the number of genotyped SNPs within the MICA and MICB genes a denser 
map of the area may be obtained. This may highlight associated SNPs which are not in strong 
LD with the original set of TagSNPs investigated. In order to detect these additional SNPs the 
size of the cohort used would also need to be increased to ensure sufficient power (see 
Chapter 2, section 2.8.1). Furthermore the additional SNPs could be screened for LD with 
HLA class II to determine if new associations were independent of the already demonstrated 
HLA class II associations (see Chatper 3).  
 
HLA-B, and HLA-C lie close to the MICA and MICB genes and have also shown to be 
strongly associated with GD (Simmonds et al. 2007). Screening of these genes, in addition to 
other portions of the HLA class I gene region such as HLA-A would therefore be beneficial. 
Again these areas could be assessed for LD with both the MICA and MICB genes and also 
the HLA class II region. 
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CHAPTER 5: DISCUSSION 
Whilst much work has been done to investigate autoimmune thyroid diseases (AITDs) 
Graves’ disease (GD) and Hashimoto’s Thyroiditis (HT) in combined datasets and to 
investigate GD, there has been minimal work on the determination of the causal factors of HT 
alone (see Chapter 1). Although there is a commonality between HT and GD in that they are 
both exhibit autoimmune attack against the thyroid there are a few differences, a fact which 
highlights the need for separate investigation of these two diseases.   
5.1 Discussion 
 
Several studies have previously been conducted which investigate association of the HLA 
class II region with HT however they have all been on small data sets and many have been in 
mixed GD and HT datasets (Moens et al. 1978, Weissel et al. 1980, Farid et al. 1981, 
Stenszky et al. 1987, Tandon et al. 1991, Petrone et al. 2001, Hunt et al. 2001, Tomer et al. 
2003a). The primary aim of this study therefore was to perform a candidate gene association 
study to determine the genetic causal variants present in the HLA class II region in a large HT 
only cohort. 
 
Strong association of both the DR4 haplotype as a whole and the strong association of its 
component alleles (DRB1*04, DQB1*0301/4 and DQA1*03011/12) were detected within this 
study and serve to reinforce smaller previous studies that identified the DR4 haplotype as a 
causal factor in two Caucasian HT cohorts (Petrone et al. 2001, Farid and Thompson 1986).   
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Although previous studies have found association of the DR4 haplotype and alleles in both 
Type 1 Diabetes (Cucca et al. 2001) and Rheumatoid arthritis (Gourraud et al. 2006) no 
association has been observed in GD. The fact that the DR4 haplotype appears to be a 
common susceptibility locus to autoimmune disease (AID) in general but not for the more 
specific grouping of autoimmune thyroid disease may be explained by the different nature of 
the diseases in question. Whilst HT and GD share a commonality, in that they affect the same 
organ, they have very different effects on the thyroid, with cellular destruction a key feature 
of HT but notably absent in GD. The differences between HT and GD are further highlighted 
in this study by the lack of association of DR3, a strongly associated GD locus. 
 
HT and Type 1 Diabetes are centred around the destruction of cells pertaining to a specific 
organ. Rheumatoid arthritis similarly is centred around cellular destruction of specific tissue 
types. It may be that the DR4 susceptibility locus plays a role in this specific aspect of AID by 
affecting the normal patterns of telomeric shortening and as a result replicative senescence of 
T-cells and granulocytes. A theory also supported by the work performed by Schonland et al 
concerning the effects of DRB1*04 on telomeric shortening (Schonland et al. 2003).  
   
As the HLA region contains immune system regulatory genes throughout the entire region it 
is unsurprising that associations have been found in genes outside of HLA class II. This, in 
combination with the strong LD exhibited in the HLA gene region meant it was also 
important to assess whether any associations in the HLA class II region were independent of 
possible associations in the HLA Class I region. Hence the secondary aim was to perform a 
preliminary study into the associations present in the HLA Class I region with HT.   
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A small association was found for the rs2853975 SNP in the MICA gene with HT and no 
other associations were detected. This finding is similar to that of the only other previous 
study concerning association of MICA with HT where a small positive correlation was 
observed for the A9 allele (Ide et al. 2007). This may be a true small, independent association 
however no significant associations have as yet been found for either MICA or MICB with 
any of the other AIDs. It is therefore prudent to consider the possibility that this result is 
either a false positive or is a result of the strong LD seen in the HLA region. To fully 
investigate the LD full linkage analysis needs to be performed between this area and the 
associated alleles in the HLA class II region. It is also necessary to perform an in-depth 
association study of the whole HLA Class I region and once again perform a linkage analysis 
to determine if any associations are independent of the known HLA class II associations.    
 
Phenotype correlations 
5.2 Future Work 
Whilst a strong association was found for the DR4 haplotype with the cohort in general it may 
be that a specific feature such as age of onset of HT is influenced by this causal factor. It may 
also be that the DR4 haplotype becomes a susceptibility factor of note when found in 
conjunction with an environmental factor such as smoking. The cohort used for this study did 
not provide sufficient phenotype data to perform an in depth phenotypical analysis of the 
results with only TSHR serum antibody presence and presence of diffuse goitre correlations 
analysed. Although my work has been performed on the largest HT dataset collected 
worldwide, to date, it would be prudent to perform further work using a cohort with complete 
data for age, sex, TPO and Tg serum antibody levels and smoking. If the size of the cohort 
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was also increased then it would also be possible to perform phenotype genotype correlations 
using finer subdivisions of the phenotypes and environmental factors. 
Whilst a significant difference in the genetic causal factors between those for GD and HT has 
been found in this study HT remains part of the general group of AIDs. It is known that there 
are several common susceptibility factors between the AIDs; hence it would also be beneficial 
to investigate the incidence of other AIDs within the probands immediate family. With this 
information the correlation of AID incidence and discovered HT genetic causal factors could 
be investigated. This would help determine whether the presence of another AID was 
enriching HT patients for AID susceptibility loci.   
 
HLA Class I loci 
Whilst a preliminary study into the association of HLA Class I encoded MICA and MICB loci 
with HT was performed as part of this investigation, the full gene region was not explored. 
The initial results suggest that due to lack of strong association in the MICA and MICB genes 
the associations found in the HLA Class II region were independent and not reliant on the 
associated loci being in LD with potential causal factors in the HLA Class I region. The genes 
investigated, MICA and MICB were however non-classical HLA Class I genes and an 
extensive investigation of both the classical HLA Class I genes and the remaining non-
classical HLA Class I genes is required to fully rule out LD as the cause of the reported HLA 
class II associations. This is particularly important following the work performed by 
Simmonds et al. which showed the association of HLA-C with GD to be stronger than the 
effects of associated HLA class II (Simmonds et al. 2007).    
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To investigate classical HLA class I genes the photoyping method of allele specific PCR 
could be used. This is the same method as described in chapter 3 for the investigation of HLA 
class II associations. The alleles used would be those detailed in Bunce et al (Bunce et al. 
1995). For non-classical HLA class I genes the Tag SNP method detailed in chapter 4 for the 
investigation of the non-classical HLA class I genes MICA and MICB may be used. 
Alternatively HLA SNP chip panels, such as those designed for the WTCCC non-
synonymous SNP screen (WTCCC 2007) or those commercially available from companies 
such as illumina (illumine, N America), may be used to screen the entire HLA region.  
 
Genome Wide Scans 
Further investigation into the HLA region and other candidate genes such may only complete 
part of the picture. As HT is a multigenic disease where the two, three or multi-hit mutational 
hypothesis may apply, it is important to fully investigate all possible sources of genetic causal 
variants. Previously genome-wide screens have been used to investigate entire genomes for 
loci which show signs of association with disease. One method, based on short tandem repeats 
which are composed of di-, tri- or tetra-nucleotide repeats known as microsatellites, has been 
used to investigate GD,  HT and common AITD loci  (Tomer et al. 2003a, Tomer et al. 1999, 
Tomer et al. 1998). The first of these studies produced two possible susceptibility loci for HT 
(HT-1 (13q32) and HT-2 (12q22)), three for GD and one for AITD (Tomer et al. 1999). When 
this genome screen was repeated with an expanded dataset the results changed dramatically. 
One locus for HT (HT-1) and one for locus for GD were not replicated and three new 
susceptibility loci were suggested, D7S502 (7q), D8S284 (8q) and D10S537 (10q) (Tomer et 
al. 2003b). These inconsistencies highlight the danger of using genome-wide screens to assess 
causal factors for complex diseases. In monogenic diseases this method can provide a definite 
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locus for further fine mapping however in complex diseases where the frequency of each 
susceptibility loci may be low it is easy to gain false positives and miss legitimate association 
loci.  
 
Whilst the precise method may be flawed the idea of scanning the entire genome to hunt out 
causal loci is sound and could produce susceptibility loci which would not have been 
considered as candidate genes. A new technique, genome wide association studies, whereby 
association analysis is performed across the entire genome may provide a means to rectify the 
flaws of the genome-wide screen method (Duerr et al. 2006, Hampe et al. 2007, Sladek et al. 
2007, Gaffney et al. 1998, Jorgenson and Witte 2006, Steer et al. 2007). This method allows 
for association analysis to be performed on over 500,000 SNPs in large cohorts of around two 
to three thousand samples. Although the HT cohort used in this thesis is one of the largest 
used to date it is still small by comparison to those used in genome wide scans. To perform a 
genome wide association analysis a much larger cohort, one of roughly 2,000 cases and 2,000 
controls, similar to those used in other genome wide association analyses (WTCCC 2007), 
would need to be collected first to ensure sufficient power for the study. In addition 
independent similarly sized cohorts would need to be available to replicate and association 
detected 
 
Whilst it is not possible to perform a genome wide scan on an HT cohort at this time the 
results from genome wide association analyses on other AIDs may provide useful candidate 
genes which can be investigated as common AID susceptibility loci. In particular the 
Wellcome Trust Case Control Consortium’s (WTCCC) [http://www.wtccc.org.uk] association 
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studies include one performed on a large GD cohort in which 14,436 non-synonymous coding 
SNPs were typed in 1,000 cases and 1,500 controls (Burton et al. 2007). This may allow 
identification of novel AITD susceptibility loci.    
 
This study has shown a strong predisposing association of the DRB1*04, DQB1*0301/4 and 
DQA1*03011/12 loci with HT. Furthermore, the DR4 haplotype (DRB1*04-DQB1*03-
DQA1*03) was shown to have a predisposing effect. Weaker predisposing effects and 
protective effects were also observed in this area demonstrating the importance of the genetic 
factors in the HLA class II region for HT. As only a small association was seen in the MICA 
region and no associations were observed in the MICB region further work is required to 
clarify the association in the HLA Class I region. Larger datasets are now required, combined 
with more thorough screening of the entire HLA region in order to determine the exact 
location and extent of susceptibility loci within this region.  
5.3 Conclusions 
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APPENDIX 
 
 
6.1 Disclaimer 
 
Collection of AITD samples 
All UK AITD samples were collected by specialist doctors and nurses from clinics in 
Birmingham, Bournemouth, Cambridge, Cardiff, Exeter, Leeds, Sheffield, and Newcastle. 
 
DNA Extraction and quantification 
All procedures of blood pelleting, DNA extraction and PicoGreen® were performed by Dr 
Joanne king, Miss Helen Foxall, Ms Sarah Gibson, Dr Matt Simmonds, Mr Paul Newby and 
myself. 
 
 
6.2 Solutions 
 
Reagent A:    2L distilled H2O 
     275g Sucrose 
 2.5ml1.0M Tris HCL pH8.0 
 2.55ml 4.9M MgCl 
 25ml TritonX 
 
Reagent B:    200ml 1.0M Tris HCL pH .0 
     60ml 0.5M EDTA pH 8.0 
 15ml 5.0M NaCl 
 205ml distilled H2O 
     20ml 25% SDS. 
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5M Sodium Percholate:  200ml distilled H2O 
     140.46g NaCl O4 
 
T.E. Buffer:    1.0 ltr distilled H2O 
 186.1g EDTA 
 10g NaOH 
 
Loading Buffer:   0.25g bromophenol blue 
40 sucrose 
Made up to 100mls with distilled water 
 
TDMH:   169μl 10 x buffer 
12μl dNTPs (200 μM) 
135μl 25mM MgCl2 
334μl distilled water  
 
6.3 Calculations 
Chi-squared  
 χ2 = (ad-bc)2 x (a+b+c+d)/(a+d)(b+c)(a+b)(c+d) 
 
Fishers Exact Probability Test 
P= (a+b)!(c+d)!(a+c)!(b+d)!/a!b!c!d!(a+b+c+d)! 
 
Woolf’s method of OR calculation 
 OR=(a+0.5)(d+0.5)/(b+0.5)(c+0.5) 
 
95% Confidence intervals 
95% CI = (lnOR±1.96√(1/a + 1/b + 1/c + 1/d))
  
6.4  HLA class II primers used to type the DRB1, DQA1 and DRB1 regions 
Primers used to type DRB1 region 
DRB1 Allele(s) Amplified Forward Primer(s) Reverse Primer(s) 
DRB1*0101/2/4 CCGCCTCTGCTCCAGGAG TTGTGGCGCTTAAGTTTGAAT 
DRB1*0103 CCCGCTCGTCTTCCAGGAT TTGTGGCGCTTAAGTTTGAAT 
DRB1*1501-5 CCACCGCGGCCCGCGC TCCTGTGGCAGCCTAAGAG 
DRB1*1601-6 CTCCGTCACCGCCCGGT TCCTGTGGCAGCCTAAGAG 
DRB1*03011/012/2/3/4/5, 1107 GTCCACCCGGCCCCGCT GTTTCTTGGGTACTCTACGTC 
DRB1*0301/4 CTGCACTGTGAAGCTCTCCA GACGGAGCGGGTGCGGTA 
DRB1*0302/5, 1302/5, 1109/20, 
1402/3/9/13/19 CTGCACTGTGAAGCTCTCAC TACTTCCATAACCAGGAGGAGA 
DRB1*0401-22, 1410, 1122 CTGCACTGTGAAGCTCTCAC GTTTCTTGGAGCAGGTTAAACA 
 
CTGCACTGTGAAGCTCTCCA 
 DRB1*0701 CCCGTAGTTGTGTCTGCACAC CCTGTGGCAGGGTAAGTATA 
DRB1*0801-11, 1415 CTGCAGTAGGTGTCCACCAG AGTACTCTACGGGTGGTGTT 
 
TGTTCCAGTACTCGGCGCT 
 DRB1*0901 CCCGTAGTTGTGTCTGCACAC GTTTCTTGAGCAGGATAAGTTT 
DRB1*1001 CTGCACTGTGAAGCTCTCAC CGGTTGCTGGAAAGACGCG 
DRB1*1101-21, 1411 CTGGCTGTTCCAGTACTCCT GTTTCTTGGGTACTCTACGTC 
  
TTCTTGGAGTACTCTACGGG 
   DRB1*1201/2/3 CTGTTCCAGGACTCGGCGA AGTACTCTACGGGTGGTGTT 
DRB1*1301/2/4/8/15-17/19/20/22, 1416, 
1102/3/11/14/16/20/21 
TCCACCGCGGCCCGCTC GTTTCTTGGGTACTCTACGTC 
 
TTCTTGGAGTACTCTACGGG 
DRB1*1301/2/8/9/16/20, 1116/20, 1416 TCCACCGCGGCCCGCTC GTTCCTGGACAGATACTTCC 
 
CCACCGCGGCCCGCGC 
    
   
   
 
 
  
  
 
 
 
 
  
   DRB1 Allele(s) Amplified Forward Primer(s) Reverse Primer(s) 
DRB1*1301/2/(6)/10/15/16, 1116/20, 
1419/21 
CCCGCTCGTCTTCCAGGAT TACTTCCATAACCAGGAGGAGA 
TCCACCGCGGCCCGCTT 
 DRB1*1305/6/10, 1109, 1419/21 ACCGCGGCCCGCCTGTC TACTTCCATAACCAGGAGGAGA 
 
TCCACCGCGGCCCGCTT 
 DRB1*1303/10, 1419/21 TCCACCGCGGCCCGCTT GTTTCTTGGGTACTCTACGTC 
DRB1*1303/4/12/21, 1413 TGTTCCAGTACTCGGCGCT GTTTCTTGGGTACTCTACGTC 
   DRB1*1305/7/11/14/18/21, 
1101/4/6/9/10/(11)/12/15 CCCGCCTGTCTTCCAGGAA GTTTCTTGGGTACTCTACGTC 
DRB1*1301/2/5-9/10/11/14-16/18/19/20/22, 
1402/3/6/9/12/14/17/19-21, 0301-5 CTGTTCCAGTACTCGGCATC GTTTCTTGGGTACTCTACGTC 
DRB1*1401/3-5/7/8/10-12/14/15/18, 1318, 
0809, 1117 
TCTGCAATAGGTGTCCACCT GTTCCTGGACAGATACTTCC 
CTGCAGTAGGTGTCCACCAG GTTCCTGGAGAGATACTTCC 
   DRB1*1401/7/16 CTGTTCCAGTGCTCCGCAG GTTTCTTGGGTACTCTACGTC 
DRB1*1402-3/6/9/12/13/17, (1418/19/21), 
(0301/2/3/5), 1318 CTGCAGTAGGTGTCCACCAG TACTTCCATAACCAGGAGGAGA 
 
CCGCCTCTGCTCCAGGAG 
 
  
Primers to type DRB3, DRB4 and DRB5 regions 
 
 
 
 
 
 
 
 
  
  
DRB Allele(s) Amplified Forward Primer(s) Reverse Primer(s) 
DRB5*0101/2, 0201/2/3 GCTGTTCCAGTACTCGCG GTTTCTTGCAGCAGGATAAGTA 
DRB3*0101 CTGCAGTAATTGTCCACCCG TTTCTTGGAGCTGCGTAAGTC 
DRB3*0201/2/3 CCCGCGGTACGCCACCTC GGAGTACCGGGCGGTGAG 
DRB3*0201, 0301 CTGCACTGTGAAGCTCTCCA GTTTCTTGGAGCTGCTTAAGTC 
DRB4*0101101, 0102/3 CTGGTACTCCCCCAGGTCA GATCGTTCGTGTCCCCACAG 
DRB4*0101102N TCCCCCAGGTCACTGTTGT GATCGTTCGTGTCCCCACAA 
  
Primers to type DQB1 region 
 
 
 
 
 
 
 
 
 
  
  
DRB1 Allele(s) Amplified Forward Primer(s) Reverse Primer(s) 
DQB1*0305 TGCACACCGTGTCCAACTC GCTACTTCACCAACGGGACC 
DQB1*02 CGTGCGGAGCTCCAACTG GTGCGTCTTGTGAGCAGAAG 
DQB1*04 TGGTAGTTGTGTCTGCATACG GCTACTTCACCAACGGGACC 
   DQB1*05 CCCGCGGTACGCCACCTC ACGGAGCGCGTGCGGGG 
   
DQB1*0601/2/3 
CCGCGGAACGCCACCTC TTTCGTGCTCCAGTTTGGC 
 
GACGTGGGGGTGTACCGC 
   
DQB1*0603-9 
TGCACCCCTGTCCACCG GGAGCGCGTGCGTCTTGTA 
 
GGAGCGCGTGCGTCTTGTA 
   DQB1*0301/4 CGTGCGGAGCTCCAACTG GACGGGCGCGTGCGTTA 
DQB1*0302 CTGTTCCAGTACTCGGCGG GTGCGTCTTGTGACCAGATA 
DQB1*03032 CTGTTCCAGTACTCGGCGT GACGGGCGCGTCGCTCT 
  
Primers to type the DQA1 region 
 
 
 
 
 
 
 
 
  
  
DRB1 Allele(s) Amplified Forward Primer(s) Reverse Primer(s) 
DQA1*0101/4 CATGAATTTGATGGAGATGAG ATGATGTTCAAGTTGTGTTTTGC 
DQA1*0102/3 CATGAATTTGATGGAGATGAC ATGATGTTCAAGTTGTGTTTTGC 
DQA1*0201 ACGGTCCCTCTGGCCAGTT CAGGATGTTCAAGTTATGTTTTAG 
DQA1*03011/12 TTCACTCGTCAGCTGACCAT CAAATTGCGGGTCAAATCTTCT 
DQA1*0302 TTCACTCGTCAGCTGACCAC CAAATTGCGGGTCAAATCTTCT 
DQA1*0401 ACCCATGAATTTGATGGGC CACATACCATTGGTAGCAGCA 
DQA1*05011/12/13, 0502 CGGTCCCTCTGGCCAGTA AGTTGGAGCGTTTATCAGC 
DQA1*0601 ACGGTCCCTCTGGCCAGTT GGTCAATCTAAATTGTCTGAGA 
  
6.5 SNPs used to genotype the MICA and MICB gene regions 
SNPS used to gentotype the MICA gene  
 
 
 
 
 
 
 
 
 
 
  
  
SNP Sequence 
rs1131896 AGGAACTACGGCGATATCTAGAATCC[A/G]GCGTAGTCCTGAGGAGAACAGGTAC 
rs1131904 CTGCAAAATGTTAGTAGATATGAGGC[A/G]TTTGCAGCTGTGCCATATTAATTGG 
rs2256175 CTGCCCACTCCTCACCTGCAGCAGGA[A/G]GATGCCACAGCTGGGCGTTTGACCC 
rs2523497 AAAAGGTAGAAGTAACCCAAGTGTCC[A/G]TTGTCTGAGGGATGGATAACCAAGA 
rs2844514 ATTCCCCAACTTTCATCCCCTGTTAT[A/G]GAAGCCTTGTCACCAACATGCCTAT 
rs2844518 GGGGCCACCATGAGGCAGGGTCCAGA[A/G]CAGGCATCTGCACTGGAGGGGAGGG 
rs2844519 AAAGGGAAGATGCCAGCCAGAAGCAG[A/G]AAGACCGGGCCCAGCCCCATGGCCC 
rs2853975 TTGTGTTTATTCCCTGGGGACTTTTC[A/T]CTCTTCAGTTGCTCCAAAACCAGAT 
rs2853977 ACACTGGATGGTCCAGTCCCTGACCC[A/T]CTGTCTTTATCCAGTGGCTCTAACA 
rs6934187 GGCCTCCCTGAGTTTCTTGCAGATGA[C/G]ATGGATGAGTAGATAAGCAGATGTC 
  
SNPs used to genotype the MICB gene  
 
 
SNP Sequence 
rs2855812 CTGAAAAGATGGACTTACTCTTTGA[G/T]ACCCTGTCACCTGCCCACCCCAGTG 
rs3130615 AAGACGTAGGTGACAAGGCTGCTGG[A/G]ACAGGGGATGGAAGCTGGGGTATTT 
rs3131638 ATAAGGGGTTCCTGCCTCTGTGTTTT[G/T]TTTTTCCTCTATTAGATTATCTGGC 
rs7383312 CGTGTATGTGGAGTACTATTCAGCCA[C/T]CATGTCATTTGCAAAGAACTGGAGG 
rs9267390 GAGTGCTGGAGCATATGACAGCTCT[A/G]TTATATTTTTAGTTTTTGGAAGAAC 
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